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 3 
Summary 
 
 
Glioblastoma multiforme (GBM) is the most frequent and the most aggesssive 
malignant neoplasm of the human central nervous system (CNS), with a median survival of 
less than one year. These neoplasms are radio- and chemo-resistant, and are highly invasive, 
which renders their surgical resection inefficient. Because of the lack of efficiency of those 
conventional therapies, GBM patient prognosis has remained unchanged for the last forty 
years. Gene amplification and overexpression of the ErbB-related tyrosine-kinase receptor for 
epidermal growth factor (EGFR) are found in 40-50% of GBM, and correlate with 
progression of the disease and poor response to treatment. PKI-166 and AEE788 are small 
molecular weight protein kinase inhibitors (PKIs) of EGFR activity that can therefore 
potentially control progression of GBM.  
In fact, PKIs against ErbB receptors did not induce apoptosis on GBM cells in vitro. 
We further assessed a pro-apoptotic effect of anti-ErbB PKIs in the presence of the 
microtubule stabilizer and cytotoxic drug patupilone applied at suboptimal doses. 
Combination of AEE788 with patupilone led to a synergistic induction of apoptosis in 50% of 
glioma cell lines. In the remaining resistant lines, the simultaneous use of PKIs against 
downstream EGF signaling mediators Phosphatidylinositol-3 kinase (PI3K) and mitogene-
activated kinase/ERK kinase (MEK), Wortmannin and U0126, respectively, potentiated 
tumor cell apoptosis. The use of these particular drug combinations allows a novel approach 
for the treatment of glioblastoma patients. 
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Introduction 
 
1.1 Cancer: general background 
 
Cancer is a major cause of death in Western countries. For instance, in 2004, cancer 
was determined to be the cause of approximately 25% of deaths in Switzerland, while 15 000 
new cases were diagnosed, according to the Federal Statistic Office (Quinto, 2004). Most 
cancers still lead to death, despite the progress in basic and clinical research, current treatment 
results only in a modest prolongation of life.  
Environmental factors such as exposure to carcinogens (tobacco smoke) (Witschi et 
al., 1995), food (Johnson, 2002) or UV light (Fisher & Kripke, 1977) play a critical role in the 
development of cancer. Carcinogenesis results from the accumulation of genetic alterations 
that target genes involved in the regulation of the cell-cycle, survival and genome integrity.  
It is believed that a gain of oncogene function together with the loss of tumor-
suppressor function cooperates to promote tumor development. Physiologically, many 
oncogenes accelerate cells during the G1/S phase of the cell cycle whereas tumor-suppressor 
genes act as blockers of cell growth and proliferation. Inactivation of tumor-suppressor genes 
requires alterations in both alleles as theorized by Knudson (2001). Alterations of oncogenes 
and tumor suppressor genes result from various genetic mechanisms, such as gene 
amplification, gain of function mutations, ectopic expression by translocation of oncogenes, 
and loss of heterozygosity (LOH), loss of function mutations (Pihan & Doxey, 2003) and also 
transcriptional silencing for tumor-suppressor genes (Merlo et al., 1995; Herman & Baylin, 
2003). 
It is now widely accepted that the neoplastic process arises from a single cell and 
tumor progression results from the accumulation of acquired genetic alterations in tumor 
cells, allowing the selection of clones that have acquired growth advantage. This process 
leads to the progressive conversion of normal cells into cancer cells (Nowell, 1976). 
Mutations lead to self-sufficiency in growth signals, insensitivity to anti-growth signals, 
limitless replicative potential, escape of apoptosis and sustained angiogenesis, all factors 
considered to be hallmarks of cancer cells (Hanahan & Weinberg, 2000). Upon an exogenous 
or an endogenous stress signal, a normal cell induces cell-cycle arrest and either repairs DNA 
damage or triggers the apoptotic machinery. In contrast, a cancer cell no longer induces 
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efficient cell cycle arrest and apoptosis, as a result of mutations accumulated in cell cycle, 
DNA repair and pro-apoptotic genes. 
Mutations in cancer genes can be present in germline DNA, resulting in hereditary 
predispositions to cancer. Genes such as NF-1, NF-2, PTEN, TSC1/2, MLH1/MSH2 (Turcot 
syndrome), p53 (Li-Fraumeni syndrome) and Rb (He et al., 1995) have been related to 
familial cancer syndromes (Fearon, 1997). On the other hand, cancer gene mutations can 
occur in a single somatic cell, resulting in the prevalent sporadic tumors. Among such genes 
involved in gliomagenesis are Rb (He et al., 1995), CDKN2A which encodes p16/p14 
(Labuhn et al., 2001), p27 (Alleyne et al., 1999) and HDM2 (Vogelstein & Kinzler, 2004). 
 
1.2 Glioblastoma multiforme (GBM) 
 
a. Main features 
The most common neoplasms of the central nervous system (CNS) are of astrocytic 
origin. Like tumors of other cellular types, they show also resistance to chemo- and radio-
therapy (Shapiro et al., 1989). However, in contrast to other tumor types, they rarely 
metastasize via the cerebrospinal fluid (Giordana et al., 1995), but show diffuse infiltration 
and rapid invasion of neighboring brain structures (Burger et al., 1988). 
The World Health Organization (WHO) classification into four grades (I-IV 
astrocytoma) is based on the degree of malignancy defined by histopathological criteria. 
Grade I is the benign pilocytic astrocytoma that rarely progresses to more advanced stages, 
whereas grades II to IV are malignant and infiltrate into the brain. Low-grade astrocytoma 
grade II patients have a survival time between 3 and 10 years. Grade III astrocytomas are 
anaplastic, with a mean survival of 2-5 years, and grade IV tumors also known as 
glioblastomas (GBM) are the most malignant forms, with a median of 10 to 12 months. The 
incidence rate per 100,000 population/year, adjusted to the World Standard Population, was 
3.32 in males and 2.24 in females (Ohgaki et al., 2004). 
Progress in the field of molecular neuro-oncology revealed that the most relevant 
genes involved in gliomagenesis are those encoding growth factor receptors (e.g. EGFR), 
components of the cell cycle machinery (Rb, Cdk4, and the Cdk inhibitor p16INK4a), and 
regulators of apoptosis (p53, HDM2, p14ARF and PTEN) (Maher et al., 2001). These 
alterations have been shown to confer growth advantage not only to gliomas, but also to 
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tumors of various origins, leading to uncontrolled cell proliferation, high potential of invasion 
and drug resistance.  
 
b. Molecular and genetic aspects of glioma development 
GBMs are divided into two subgroups based on clinical features (Scherer, 1940). On 
one hand, primary GBMs arise as a de novo process, without a pre-existing lesion. On the 
other hand, the secondary GBMs regarded as grade IV astrocytomas, develop progressively 
from lower grade astrocytomas generally over a period of 5-10 years (Collins 1998 & 
Rasheed et al., 1999). Remarkable insights into the origin and the behaviour of gliomas have 
emerged from in vitro cellular and in vivo animal models. It appears that GBMs can arise 
from adult neural progenitor cells and/or dedifferentiated astrocytes (Maher et al., 2001). 
Astrocytes or oligodendrocytes may undergo dedifferentiation to multipotent progenitor cells 
as the result of an accumulation of genetic mutation(s) (Maher et al., 2001; Bachoo et al., 
2002) that alter  signal transduction pathways activated by receptor tyrosine kinases (RTKs) 
and cell cycle arrest regulation (Figure 1). Taken together, these observations have allowed 
novel cellular and molecular subclassifications that provide bases to improve diagnosis 
(Hermanson et al., 1992; Leihues & Cavenee, 2000; Maher et al., 2001; Holland, 2001). 
 
Receptor tyrosine kinases 
Components of mitogenic pathways, in normal and neoplastic cells, are activated by 
protein kinases located upstream in the signaling cascade. Among the growth factors and their 
receptors overexpressed in human malignant astrocytomas are the epidermal growth factor 
receptor (EGFR), the platelet-derived growth factor (PDGF) and its receptor, PDGFR. The 
EGFR gene is amplified in approximatively 50% of GBMs (Maher et al., 2001), 40% of those 
express a truncated form of EGFR, that lacks a large portion of the extracellular ligand 
binding domain, resulting in a constitutive activation of the receptor (Ekstrand et al., 1994). 
On the other hand, PDGF and PDGFR are expressed at high levels by malignant astrocytoma 
cell lines and tissue without gene amplification (Guha et al., 1995), suggesting autocrine 
and/or paracrine stimulation. 
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From these observations the idea has emerged to target growth factor pathways as a 
potential strategy of cancer therapy. The development of selective protein kinase inhibitors 
that can block or modulate diseases caused by abnormalities in these signaling pathways is 
widely considered as a promising approach for drug development. Two famous examples of 
tyrosine kinase activation have been used as targets for screening potentially inactivating low 
molecular weight compounds (Capedeville et al., 2002). The BCR-ABL fusion protein, which 
results from the translocation of chromosomes 9 and 22 (Philadelphia chromosome) has been 
defined as the cause of chronic myeloid leukemia (CML) (Rowley, 1973). This allowed the 
identification of a new selective tyrosine kinase inhibitor, Gleevec. Interestingly, Gleevec has 
also been shown to block c-KIT constitutive activation in gastrointestinal stromal tumor 
(GIST) (Tuveson et al., 2001). Following the same approach, mutations of EGFR in non-
small cell lung cancer (NSCLC) are targeted by Gefinitib. These were the first examples of 
molecules that have resulted from the translation of basic cancer research into cancer 
therapeutics (Capedeville et al., 2002; Linch et al., 2004). 
 
Cell-cycle deregulation 
A hallmark of high-grade astrocytomas is their high mitotic activity. As a key 
checkpoint of mitosis, G1/S phase transition is regulated by the retinoblastoma tumor-
suppressor (RB). Not surprisingly, the cyclin-dependent kinase inhibitor regulatory circuit 
RB– CDK4/6– p16INK4a is frequently disrupted in brain tumors. Homozygous deletion of 
p16INK4a and p14ARF, both encoded by the same gene, CDKN2A are observed in 41% of GBMs 
(Labuhn et al., 2001), while the combined amplification of CDK4 and loss of RB are 
identified in 14 to 33% of GBMs (He et al., 1995; Fulci et al., 2000). The remaining GBMs 
are due to mutations in other genes of this pathway (cyclin D1 and CDK6) (Costello et al., 
1997; Buschges et al., 1999). Taken together, GBMs harbour mutations in the 
p16INK4A/CDK4/RB pathway, whereas such mutations are rare in low-grade astrocytomas.  
The tumor suppressor p53 regulates cell cycle progression and apoptosis (Fischer, 
2001). Early loss of p53 in astrocytomas confers evasion of apoptosis. Healthy cells exposed 
to genotoxic stress either enter cell-cycle arrest or undergo apoptosis. Patients with the 
inherited Li-Fraumeni cancer syndrome carry a germ line mutation in the TP53 gene and are 
predisposed to the development of various tumors, including astrocytomas (Malkin et al., 
1990; Srivastava et al., 1990). Mutations in TP53 are uniformly found in more than 60% of 
all grades of sporadic astrocytomas (Sidransky et al., 1992).  
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Phosphatase and tensin homolog (PTEN) and Akt/PKB 
LOH on chromosome 10 is the most frequent genetic alteration found in GBM. It was 
crucial to understand to which extent the loss of genetic material of this chromosome 
contributes to tumor development. Mutations in PTEN occur in approximatively 30% of 
primary GBMs, and only in 4% of secondary GBMs (Ishii et al., 1999; Tohma et al., 2000). 
The tumor-suppressor gene PTEN is located on chromosome 10q23.3. It negatively regulates 
PI3K by dephosphosphorylating phosphatidylinositol triphosphate (PIP3) (Fig. 5). In PTEN 
mutant cells, PI3K hyperphosphorylates AKT (Maehama & Dixon, 1999) a modulator of 
survival, invasion and proliferation (Maier et al., 1999; Ignatoski et al., 2000). PTEN was 
shown to mediate growth inhibition (Furnati et al., 1998) and to play a role in cell motility 
(Maier et al., 1999). Finally, mutant PTEN status may be linked to an aggressive clinical 
course (Lin et al., 1998; Rustia et al., 2001).  
  
Mismatch repair genes 
The vast majority of glioblastomas are sporadic, with a few exceptions, e.g. the rare 
Turcot’s syndrome predisposes to glioblastoma (Hamilton et al., 1995). Turcot’s syndrome is 
characterized by mutations in the DNA mismatch-repair genes mutS homologue 2 (hMSH2) 
or mutL Homologue 1 (hMLH1) operative during cellular replication (Jiricny & Nystrom-
Lahti, 2000) while mutations at these loci are rarely observed in sporadic glioblastomas 
(Merlo, 2003). Survival of GBM patients with germline mutations in mutator genes is 
exceptionally high (3, 6 and 14 years as compared to about 8 months in sporadic cases) 
(Hamilton et al., 1995), but not in all cases (Merlo et al., 1996) 
 
1.3 Glioma animal models 
 
a. Introduction 
Over the last 15 years, cellular, molecular and genetic comparison between glioma 
cell lines and normal brain tissue has provided essential insight into the biology of the 
disease. More recently, the microarray technology has allowed the identification of thousands 
of genes differentially expressed in glial tumors (Lal et al., 1999). However, this approach 
only reveals an association between genetic expression changes and the neoplastic phenotype 
and from a mechanistic point of view, and does indicate genetic alterations that initiate 
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gliomagenesis. Such questions can only be solved by stably introducing the suspected genetic 
alterations into an in vivo experimental system and further testing for their ability to develop 
glial tumors, spontaneously, or in a given genetic background. For this reason, several genetic 
alterations hypothesised to initiate glioblastoma development have been stably introduced 
into the genomes of mice. 
These animal models were especially adapted to these needs, they have several 
characteristics that make them valuable test systems, including defined and reproducible 
location of tumor formation, rate of tumor growth and life span. Animal models do not only 
provide information on the potential causes of astrocytoma formation, but they may also 
allow to provide novel targets for therapy and tumor-bearing animals for preclinical trials. 
 
b. Models 
Several transgenic mice that ectopically express oncogenes and that have been 
targeted for tumor suppressor genes (knock out) have been recently developed. A summary of 
mouse brain tumor models has been described in the Annex I. Interestingly, Holland and co-
workers have shown that the co-expression of activated RAS and AKT in normal astrocytes 
or neural progenitors cells in mice induced GBM, whereas neither AKT nor RAS alone are 
sufficient to induce such neoplasm (Holland et al., 2000). In addition, a recent study has 
shown that p14ARF loss combined with transgenic Ras and Akt in both astrocytes and glial 
progenitor cells, resulted in gliomagenesis. In this study, p16INK4A had a tumor suppressor 
function limited to glial progenitor cells (Uhrbom et al., 2005). In contrast, others have shown 
that constitutive high Ras transgene expression in astrocytes can induce gliomas while a 
moderate expression level leads to low-grade atrocytoma development (Ding et al., 2001).  
On the other hand, in GBM, loss of function of Ink4a/Arf is frequently associated with 
EGFR activation (Holland et al., 1998; Bachoo et al., 2002). While Holland and co-workers 
(1998) proposed that tumors arise more efficiently from immature glial cells, another study 
demonstrated that both mature astrocytes and neural stem cells can serve as the cell-of-origin 
for gliomagenesis (Bachoo et al., 2002). Their hypothesis that biological behaviour of GBM 
depends on disregulation of specific genetic background and not on the state of glial 
differentiation is supported by astrocytes dedifferentiation that undergo into a multipotent 
progenitor cell during tumorigenesis (Bachoo et al., 2002). 
Thus, genetic models have added significantly to the understanding of the cellular 
characteristics observed in malignant gliomas. This suggests potential ways for therapeutic 
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intervention in a broad range of tumors. This finding that different genetic alterations can 
generate malignant gliomas indicates that targeting proteins in crucial cellular pathways might 
be more successful than disrupting the function of a single protein.  
However, transgenic and knock out mice models, in which only specific genes or 
combination thereof are targeted, do not take into account the genetic instability of tumor 
cells that generates the accumulation of additional genetic alterations occurring during 
tumorigenesis. 
 
1.4 Molecular aspect of targeted therapies 
 
a. Why targeting ErbB receptors? 
The epidermal growth factor receptor (EGFR) family, also known as ErbB receptor 
family represents the subclass I of the RTK superfamily, and includes four members: 
EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4. They are normally 
expressed in a variety of tissues of epithelial, mesenchymal and neural origin, and play a 
fundamental role in cell development, proliferation, differentiation, migration and survival 
(Olayioye et al., 2000; Holbro et al., 2003). The EGFR gene, located on human chromosome 
7p11-12, encodes a 170 kDa protein (EGFR/ErbB1/HER1) (Kondo et al., 1983). 
All members of the ErbB family have in common an amino-terminal extracellular 
ligand-binding, a single hydrophobic transmembrane and a carboxy-terminal cytoplasmic 
protein kinase domain. In the absence of ligand binding, EGFR is present as monomer and as 
dimer (Sako et al., 2000). Ligand binding to ErbB receptors induces formation of different 
combinations of homo- and heterodimers, ErbB2 being its preferred partner (Graus-Porta et 
al., 1997).  
 
Signaling pathways activated by EGFR autophosphorylation 
 
Dimerization leads to activation of the intrinsic kinase domain, which results in 
phosphorylation on specific tyrosine (Tyr) residues within the cytoplasmic tail of the receptor. 
These phosphorylated residues serve as docking sites for a variety of signaling molecules 
whose recruitment leads to the activation of intracellular pathways as described in Fig. 2a and 
b (Graus-Porta et al., 1997; Yu et al., 2002).  
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It has been shown that c-Src is involved in phosphorylation of the EGF receptor on 
Tyr845, which is associated with modulation of receptor function (Biscardi et al., 1999). 
Phospho- Tyr 992 is a direct binding site for the phospholipase C-! (PLC-!) SH2 domain and 
results in activation of PLC-! mediated downstream signaling (Emlet et al., 1997). 
Phosphorylation of Tyr1045 creates a major docking site for Cbl-b that leads to assembly of 
ubiquitination machinery to the receptor, and enables receptor ubiquitination and degradation 
(Ettenberg et al., 1999; Levkowitz et al., 1999). Phospho-Tyr 1068 is a direct binding site for 
the Grb2/SH2 domain, whereas phospho-Tyr 1148 provides a docking site for Shc. Phospho-
Tyr 1068 and phospho-Tyr 1173 are the major sites of autophosphorylation, which occurs as 
a result of EGF ligand binding (Batzer et al., 1994; Rojas et al., 1996; Ward et al., 1996; 
Sakaguchi et al., 1998).  
All these sites are involved in activation of the Ras/MAP kinase signaling pathway 
(Rojas et al., 1996; Zwick et al., 1999). These phosphorylated residues in the EGFR and the 
activation of the corresponding signaling transduction pathways are summarized in Fig. 2a. In 
addition, ErbB2 was shown as the preferred heterodimerization partner within the ErbB 
family as it decreases ligand dissociation from the receptor heterodimer thus enhancing and 
prolonging the activation of the MAPK signaling pathway (Fig. 2b) (Graus-Porta et al., 1995; 
Moriki et al., 2001)  
As described in chapter 1.2.b, genetic alterations that activate RTK signaling 
pathways frequently cooperate in the course of gliomagenesis. Moreover, aberrant EGFR and 
ErbB2 expressions have been associated with advanced stages in a number of tumor types 
(Annex II) and poor patient prognosis (Slamon et al., 1987; Allred et al., 1992; Hynes & 
Stern, 1994; Salomon et al., 1995; Nicholson et al., 2001; Sjogren et al., 2001). From these 
observations, strategies to develop drugs that target EGFR/ErbB2 have been designed (Annex 
III). 
 
EGFR and glioblastoma 
 
Amplification of the gene coding for EGFR has been observed in 40-50% of primary 
primary GBMs, but is rare in secondary GBMs (Lang et al., 1994; Schlegel et al., 1994). 
Glioblastoma with EGFR gene amplification typically show simultaneous loss of 
chromosome 10 (von Deimling et al., 1992; Lang et al., 1994) as well as deletion of the 
INK4a/Arf locus (Hegi et al., 1997), while TP53 is wild-type (Fulci et al., 2000). EGFR 
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expression correlates with poor response to treatment, disease progression, and poor survival 
(Wong et al., 1992; Salomon et al., 1995; Nicholson et al., 2001). 
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Figure 2: Autophosphorylation sites on the EGFR protein. We considered 
EGF alone as ligand (A) In absence of ErbB2 monomers, activation of the 
corresponding major signaling transduction pathways after EGFR 
homodimerization. (B) In presence of ErbB2 monomers, activation results in 
EGFR/ErbB2 heterodimers. 
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Mechanisms of activation and inhibition 
 
In conclusion, aberrant activation of the mitogenic signals initiated by EGFR in 
GBMs, its mutant form and ErbB2 described in the literature (Fig. 2a and b) have been 
considered as particularly suitable targets to be inhibited by drug design for glioma therapy. 
Selective low molecular weight compounds have been developed to interact with the ATP 
binding site of the receptor as well as antibodies targeting either the extracellular ligand-
binding region of EGFR or the intracellular tyrosine kinase region. Both approaches could 
result in interference with the signaling pathways that modulate mitogenic and other cancer-
promoting responses such as cell motility, cell adhesion, invasion and angiogenesis. 
 
b. PI3K/Akt (PKB) signaling pathway  
EGFR can be activated by several ligands that lead to the activation of two disctinct 
pathways: the MAPK pathway downstream of Ras and the phospatidylinositol 3-kinase 
(PI3K) /Akt (PKB) pathway. The PI3K/Akt (PKB) pathway is a major survival pathway in 
epithelial cells, which also regulates other cellular processes such as proliferation, growth and 
cytoskeletal rearrangement (Vivanco & Sawyers, 2002). Several components of the PI3K/Akt 
(PKB) pathway are dysregulated in numerous types of human cancers. EGF stimulation 
results in the activation of PI3K, which generates phosphatidylinositol-trisphosphate (PIP3) in 
the membrane, a second messenger activating downstream pathways including AKT (Datta et 
al., 1999). AKT is a serine/threonine kinase with a wide range of substrates and is activated 
by phosphorylation at Thr308 and Ser473 (Andjelkovic et al., 1997). Thr308 is 
phosphorylated by the 3-phosphoinoside-dependent protein kinase PDK1, whereas Ser473 
was found to be phosphorylated by a DNA-dependent protein kinase (DNA-PK) (Feng et al., 
2004). Three main isoforms of AKT have been identified in mammalian cells: AKT1, 2 and 
3, AKT1 may play a role in the pathogenesis of gastric adenocarcinoma (Staal, 1987), and 
AKT2 was found to be amplified in two ovarian carcinoma cell lines (Cheng et al., 1992). In 
addition to AKT (Fig. 3), other signaling pathways are known to be regulated by PI3K 
activity and might be involved in PI3K-mediated tumorigenesis. Mutations in PIK3CA that 
encodes the p110 catalytic subunit of PI3K were also identified in 27% of glioblastomas 
(Samuels et al., 2004). 
Activation of the PI3K/Akt (PKB) pathway in brain tumors is due to excessive 
stimulation by growth factor receptors and by RAS. Loss of function of the tumor suppressor 
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gene PTEN also frequently contributes to upregulation of PI3K/Akt. In addition, active AKT 
was often detected in several human cancers in vivo (Holland et al., 2000) and has been 
linked with poor clinical outcome (Lee et al., 2001; Brognard et al., 2001; Ermoian et al., 
2002; Perez-Tenorio & Stal, 2002). Moreover it has been correlated with resistance to 
chemotherapy and radiation (Brognard et al., 2001; Clark et al., 2002). Thus, these 
observations provide strong arguments for designing drugs that specifically target the 
PI3K/Akt (PKB) signaling pathway or the RTK upstream activators. 
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c. RAS/RAF/MEK/ERK  
 In the last decade, research has been focusing on the central importance of the Ras 
pathway. In tumorigenesis, it is one of the well-characterized signal-transduction pathways. 
This pathway is stimulated by PDGFR, EGFR and other RTKs (Downward, 2003). RAS is 
active when bound to guanosine triphosphate (GTP). Adapter proteins such as Grb2 bring the 
guanine nucleotide exchange factor (GEF) Sos to the receptor to form a stable complex, 
which is required for the activation of the membrane-bound RAS. RAS is inactive when the 
Figure 3: The PI3K/Akt (PKB) signaling pathway. Activated AKT mediates the 
activation and the inhibition of several targets such as mTOR, IKK, Bad, p21, p27, 
resulting in cell growth, survival (apoptosis inhibition) and proliferation through 
various mechanisms.  
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GTP is hydrolysed to guanosine diphosphate (GDP). In GTP-bound form, RAS proteins have 
essential roles in controlling the activity of crucial signaling pathways, most notably the RAF 
pathway, which leads to the activation through phosphorylation of the mitogen-activated 
protein kinase (MAPK) also named ERK 1/2 (extracellular regulated-signal kinase 1 and 2). 
Substrates of ERK1/2 include cytosolic and nuclear proteins, reflecting the fact that they can 
be transported into the nucleus following activation (Fig. 4) (Downward, 2003). 
 Mutated and constitutively activated forms of Ras are found in around 50% of all 
human metastatic tumors (Chambers & Tuck, 1993). Although no RAS mutations have been 
detected in gliomas, high levels of Ras-GTP have been documented in high-grade 
astrocytomas (Guttmann et al., 1996; Guha et al., 1997). However, it was suggested that 
phosphorylated ERK (P-ERK) plays a role in the enhanced transformation and resistance to 
apoptosis seen in GBM (Wu et al., 1999). Targeting RAS proteins and the downstream 
signaling pathway would therefore be valuable in treating tumors that have high activity of 
ERK. 
 
 
                                   
RAS
RAF
MEK
ERK
PAR-4
Survival
Rsk Elk1 MycMNK
Growth & Proliferation
 
 
 
 
 
 
 
Figure 4: The RAS/RAF/MEK/ERK signaling pathway. The signaling pathway 
regulates survival, growth and cell-cycle progression through various mechanism such 
as RSK (p90 ribosomal protein S6 kinase), an inactivator of BAD, PAR-4, a 
transcriptional repressor of Bcl2, Elk1 and Myc, which are transcription factors 
involved in cell-cyle transition and in addition for myc, growth regulation. MNK (p38 
MAPK –dependent kinase) can activate the translation initiation complex elF-4E to 
promote protein translation and cell growth. 
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1.5 Drug resistance  
 
The recent success of Gleevec in chronic myeloid leukemia (CML) and in gastrointestinal 
stromal tumor (GIST), Herceptin (breast) and Iressa in non-small cell lung cancer (NSCLC), 
have opened new hopes in the treatment of cancer. Gleevec has established a paradigm for the 
treatment of tumors whose growth is acutely dependent on specific kinase targets. CML is 
driven by the constitutive ABL kinase activity of the fusion protein BCR-ABL resulting from 
the Philadelphia chromosomal translocation. Even if patients with late chronic-phase CML 
with which previous interferon therapy had failed (Kantarjian et al., 2002), or patients with 
accelerated-phase CML (Talpaz et al., 2002), Gleevec has been established as a safe and 
effective therapy in CML, except on the later stage of blast crisis (Sawyers et al., 2002). The 
question is whether an analogy can be made between blast crisis and GBM, if both are 
considered as the most advanced stages of CML and gliomas, respectively. It has been shown 
that tumor cells in blast crisis have accumulated additional mutations that reactivate BCR-
ABL, and therefore circumvent Gleevec treatment (Gorre et al., 2001). 
Single drug treatments are found to be insufficient, possibly because numerous genetic 
alterations have accumulated during gliomagenesis. A new strategy has to be reconsidered to 
counteract the redundant pathways. The first problem to be solved with GBM is to define the 
redundant pathways that may provide new potentially relevant targets for glioma therapy. In 
animal models, only few mediators of the growth factor/Ras, PI3K/PTEN/AKT, 
p53/ARF/HDM2 and p16/Rb/cyclinD/CDK4 pathways are targeted. In human gliomas, many 
additional genes and pathways are altered due to a high level of genetic instability leading to 
the accumulation of countless epigenetic and genetic alterations.  
This is the reason why it is now conceivable that future therapies will select various 
combinations of drugs. There are obvious advantages to such approaches: (i) the drug 
specificity should lead to a greater therapeutic window and less toxicity; (ii) the use of 
combined therapies may limit acquired drug resistance; and (iii) many of the defective 
pathways in tumor cells also affect drug or radiation sensitivity. Combined therapies using 
conventional and designed biological agents may be especially effective. 
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1.6 Specific question 
 
 Molecular genetics has allowed fundamental advances in the knowledge of cancer 
biology (Hanahan, 2000). This knowledge has been exploited with success to designate 
cancer pathways, and use them as targets for low molecular weight compounds having 
potential anti-tumorigenic effects. For example, this strategy had been applied to identify the 
Gleevec molecule treating for chronic myeloid leukemia and gastro-intestinal tumor 
(Capdeville et al., 2002), and Iressa for non-small cell lung cancer patients (Sordella et al., 
2004). However, no equivalent drug has been yet isolated for interfering with glioma 
progression. 
With the aim to find drugs for the treatment of glioma that had been identified in the 
past in other cancer types using same signaling pathways. Further, we have evaluated drugs 
used in combination for a possible additive or synergistic effects. To achieve this goal, we 
applied the following approaches: 
 
a) Protein kinase inhibition, single and combined drug approach 
We investigated for the potential anti-tumor effect of protein kinase inhibitor (PKI) 
drugs. Because of the relevance of PKI such as Gleevec, PKI-166 and AEE788 as anti-tumor 
agents, we analyzed GBM cells for cell survival and induction of apoptosis by treatment of 
these compounds alone or in combination. 
 
b) PKI and cytotoxic drug 
Combination of the most promising PKI determined in the first part of the study, as a 
possible sensitizer with a cytotoxic compound in order to obtain additive or synergistic 
induction of apoptosis on glioma cell lines. The aim is to reduce toxicity of higher drug 
concentrations. 
 
c) Targeting downstream key signaling components PI3K and MEK 
Based on mouse models, altered components of distinct signaling pathways leading to 
gliomagenesis have been defined. Therefore, if two specific pathways have to be altered to 
develop a glioma in a mouse, we conclude that we have to specifically target them in order to 
at least block the progression or even better, kill the neoplasm. Several proteins have been 
shown to confer resistance to tumor cells and should, therefore, provide novel and defined 
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targets for cancer treatment. In this context, we investigated for pro-apoptotic effect by 
targeting specific downstream components of the EGFR pathway supposed to be involved in 
resistance mechanisms observed with the different drugs tested. 
 20 
Results 
 
1. Single drug treatment 
 
a. Gleevec 
Gleevec" (Imatinib, Glivec or STI571) is registered in many countries for the 
treatment of CML in the accelerated phase or chronic phase as well as for the treatment of 
metastatic or recurrent GIST. Gleevec" is a protein-tyrosine kinase inhibitor which 
specifically targets the activated ABL oncoprotein, BCR-ABL (CML), PDGF receptor, C-
KIT (Kilic et al., 2000).  
PDGF is a ubiquitous growth factor with mitogenic properties in connective tissue and 
glial cells that also promotes angiogenesis. Under pathological conditions, the PDGF-
dependent mitogenic pathway is involved in cancer and connective tissue disorders. PDGF 
plays a fundamental role in glial development (Maher et al., 2001), while PDGF receptors are 
expressed in most types of gliomas (Hermanson et al., 1992). Of note, PDGF receptor-A 
(PDGFR-A) amplification is only found in anaplastic oligodendrogliomas with 
glioblastomatous features (Smith et al., 2000). A number of experiments using antibodies 
neutralizing PDGFR and dominant-negative mutations of either PDGF or PDGFR suggest 
that PDGFR represents a potentially important therapeutic target in GBM treatment. These 
findings provided a rationale for testing Gleevec" in human gliomas in which these pathways 
may contribute to malignant growth.  
The effect of on cell cycle profile of different glioma cell lines was determined (Fig. 
5a). The drug did not affect the cell-cycle at a concentration of 0.1 µM except in BS125.3.2 
cells, where a decrease of G1 phase accumulation was observed after 5 days. These 
observations led us to conclude that Gleevec does not affect cell cycle at this concentration. 
Since the anti-proliferative activity of Gleevec has been shown on cell lines derived from 
human bladder carcinomas, colon carcinomas and glioblastomas (Kilic et al., 2000), the drug 
was applied on glioma cell lines to confirm its effect on proliferation (Fig. 5b).  
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Figure 5: Cytostatic effect of physiological concentrations of Gleevec on glioma 
cells. (A) Cell cycle profile of glioma cell lines under Gleevec treatment. Cells were 
incubated with Gleevec during 2 or 5 days. G1 phase accumulation was determined 
by using flow cytometry. (B) Proliferation determined by Colony Forming Assay 
(CFA). SF767 and Hs683 cell lines were treated during 3 days with 0.1 µM of 
Gleevec. The size of the colonies was defined by using a colony counter that 
measures three cutoffs for colony size determination (> 10, >50, >200 µm). (C) 
Ability of Gleevec to induce apoptosis in glioma cell lines. Cells were treated with 
increasing concentrations of the drug (0; 0.1; 1 and 10 µM) during 4 days. Apoptosis 
was detected by using flow cytometry. Experiments were done in triplicate. 
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At a 0.1 µM concentration, no anti-proliferative activity was observed in the glioma 
cell lines tested. These results are in agreement with previous cell-cycle data described above. 
The cell lines were treated with increasing concentrations of Gleevec and induction of cell 
death was measured (Fig. 5c). No apoptosis was observed at a concentration of 0.1 µM. At a 
higher drug concentration (10 µM), apoptosis was detected but only in 5 out of 10 cell lines. 
Taken together, these results show that Gleevec alone is inefficient in the induction of 
glioma cell death, except at high concentrations such as 10 µM, on part of analyzed cell lines 
only.  
 
b. PKI-166 
Pyrrolopyrimidines like PKI-166 were identified as lead structures by random 
screening, and were further optimized using a pharmacophore model of the ATP-binding site 
of EGFR (Traxler et al., 1996). PKI-166 is a very potent dual inhibitor of EGFR and ErbB2 
tyrosine kinase activities, having a reasonable degree of selectivity with respect to the 
inhibition of other tyrosine and Ser/Thr kinases (Caravatti et al., 2001; Traxler et al., 2001).  
The antiproliferative activity and the in vivo antitumor activity of PKI-166 are closely 
related to the expression of the EGFR and/or ErbB2 in the human epidermoid carcinoma cells 
A-431 and in the lung carcinoma NCI-11596 (O’Reilly et al., 2000; Traxler et al., 2001). 
Based on these observations, PKI-166 is expected to be active against tumors associated with 
overexpressed or dysfunctional EGFR or ErbB2, thereby providing a rationale for testing 
PKI-166 in human glioma. The LN229 glioma cell line was treated with different 
concentrations of PKI-166 in the presence or absence of EGF in order to define the ability of 
this drug to block receptor activation. On one hand, the inhibitory effect of PKI-166 on all 
types of receptors of the ErbB family was evaluated by detection of phosphotyrosine activity 
level. On the other hand, specific inhibition of EGFR kinase activity was assayed with an 
antibody against EGFR phosphotyrosine-1173 (Fig. 6a). In the presence of 1 and 20 µM PKI-
166 and in the absence of EGF, the anti-phosphotyrosine antibody revealed residual receptor 
activity. Addition of EGF did not activate the receptor whereas EGFR was fully inhibited 
with 20 µM PKI-166. The use of the EGFR phospho-tyrosine 1173 antibody confirmed that 
LN229 can be stimulated by EGF and that activation by EGFR is blocked with 1µM PKI-166. 
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Since proliferation and invasion are fundamental features of GBM, they will both be 
used as readouts to assay effects of PKI-166. At a concentration of 1 µM, PKI-166 induces in 
LN229 cells a G1 accumulation reducing the number of cells in S phase (Fig. 6b), confirming 
the anti-proliferative effect of this compound. Regarding migration several conditions were 
tested such as PKI-166 (1 µM) and EGF alone (100 µg.ml-1) or in combination (Fig. 6c). 1 
µM PKI-166 inhibited EGF stimulated cell migration and reduced proliferation, leading to a 
complete stop of the migration of the cells. The simultaneous treatment with PKI-166 and 
EGF led to reduced migration. In fact, the cells treated with PKI-166 have a higher capacity 
of migration but lower when stimulated by EGF. The results demonstrated that PKI-166 was 
not able to fully block receptor activation. We finally tested the ability of PKI-166 to induce 
cell death. As shown in Fig. 7, a PKI-166 concentration as high as 5 µM was necessary to 
induce apoptosis whereas even after 6 days, no apoptosis happened at 1 µM. 
Taken together, PKI-166 has been demonstrated to fully block EGFR activation, even 
in the presence of EGF, and to act as an anti-proliferative and anti-migratory compound. The 
combined treatment of EGF and PKI-166 resulted in an intermediate level of migration. This 
result could be explained either by a progressive degradation of the drug during the two days, 
or due to the drug characteristics, since PKI-166 is a reversible RTK inhibitor, meaning that it 
does not covalently bind to the receptor. 
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Figure 7: Weak pro-apoptotic effect of PKI-166 on GBM cells at 1 µM. LN229 
glioma cells were incubated with increasing concentrations of the drug (0; 1 and 5 
µM). After 6 days, levels of apoptosis were determined by flow cytometry. 
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Since apoptosis was only induced at a 5µM concentration, This drug would not be the 
appropriate drug for glioma. Another important issue is to know whether targeting 
EGFR/ErbB2 should be sufficient to induce apoptosis. As a consequence, a new compound 
has been tested: a dual inhibitor of the ErbB receptor family and VEGFR-2 (KDR), named 
AEE788. 
 
c. AEE788 
AEE788 conveys an anti-proliferative and anti-migratory effect onto the tumor cells 
by blocking signal transduction via EGFR and also exerts an anti-angiogenic effect on the 
endothelial cells by inhibiting KDR/VEGFR-2 (Traxler et al., 2004). It is noteworthy that 
VEGF and its receptor, which play a crucial role during neovascularization are both expressed 
in glioblastomas (Heldin & Westermark, 1989; Plate & Risau, 1995). Inhibition of both 
VEGFR-2 and EGFR kinase activities render AEE788 highly attractive for the treatment of 
solid cancers including glioblastomas. Thus, one OG and six GBM cell lines in which the 
genetic status of the most critical cancer genes had been previously established (Ishii et al., 
1999), have been selected for further investigation.  
First, the ability of AEE788 to block EGFR/ErbB receptor activation was determined 
in LN229 cell line with increasing concentrations. A partial reduction of EGFR activation was 
already observed at low concentration (0.1 µM), while higher concentrations up to 1 µM led 
to a complete blocking of EGFR activation (Fig. 8a). Addition of EGF activated EGFR 
phosphorylation, while pre-treatment with the drug blocked the activation in a dose-
dependent manner.  
Since EGFR and ErbB2-directed inhibitor effects were associated with increased 
expression of the inhibitor of cell cycle progression p27kip1 (Peng et al., 1996; Wu et al., 1996; 
Cardiello et al., 2001; Lane et al., 2001), the effect of the drug on glioma cell proliferation 
was examined using flow cytometry (Fig. 8b) by measuring DNA synthesis in the presence of 
this drug. Cells were treated with increasing concentrations of AEE788. After 24 hours of 
treatment, all cell lines responded to the drug at a concentration as low as 2 µM except Hs683 
which needed higher concentrations. A maximal reduction of 44% was found in SF767.  
Taken together, these results indicate an anti-proliferative effect of AEE788 on the 
cell lines and further confirm a role for EGFR/ErbB2 receptor signaling in the potentiation of 
tumor cell proliferation. 
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The potential role of AEE788 as an anti-migratory compound was then analyzed. The 
ability of AEE788 to alter the migration capacity of glioma cell lines was tested by using the 
Boyden chamber technique. The cells were allowed to migrate after pre-treatment with 
AEE788 in presence or absence of EGF (Fig. 9a). The basal level of migration was reduced 
by AEE788 in six of the seven cell lines tested (LN71, LN215, U373, LN401, Hs683 and 
SF767). All cell lines responded to the drug and showed an inhibition of the motility after 
EGF stimulation when compared to EGF alone indicating a total or partial inhibition of EGF 
receptor activation. LN229, as an exception, AEE788 did not affect the basal level of 
migration even after EGF stimulation. In all the cell lines tested including LN229, the EGFR 
phosphotyrosine 1173 antibody confirmed that the drug was effective at 1 µM AEE788 and 
that activation of EGFR was blocked even when stimulated by EGF, then EGFR degradation 
process was stabilized (Fig. 9b). 
Figure 8: Effects of AEE788 on inhibition of EGFR activation and cell proliferation is 
concentration dependent. (A) AEE788 and ErbB receptor family activation. LN229 cells were 
pre-incubated for 1h with the drug and stimulated in presence or absence of EGF (100 ng.ml-1) 
for 10 min. EGFR activation was evaluated by revealing phosphorylated EGFR on Western blot 
with anti-phosphotyrosine antibody. (B) AEE788 inhibits cell proliferation in all cell lines 
tested. Cells were incubated during 24 hours with increasing concentrations of AEE788 (0; 0.1; 
1; 2; 5 and 10 µM), effect on proliferation was measured by BrdU incorporation. 
B 
A 
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As shown above, 1 µM AEE788 inhibited EGFR activation, reduced proliferation and 
inhibited the basal level of migration, making this compound to a candidate for GBM 
treatment. Further, in order to determine cell viability in a dose-dependent manner, glioma 
cell lines were exposed to higher concentrations of AEE788 (Fig. 10). No apoptosis was 
induced except in SF767 and in LN215, in which only few dead cells were detected. 10 times 
higher drug concentrations were necessary to induce apoptosis. 10 µM of AEE788 treatment 
caused a very high level of apoptosis in five out of eight cell lines, (SF767, LN215, U373, 
LN229 and LN71) with a minimum percentage of apoptosis of 65% for the LN71. Although 
SF767 and LN215 have shown some cell death at a concentration as low as 1 µM, they 
exhibited in addition a dose-dependent response in the 0.1 to 10 µM range concentration, 
whereas, others cell lines such as LN401 or Hs683 showed very low or no cell death, even at 
10 µM of drug treatment. 
These results have shown that 1 µM AEE788 blocks proliferation and migration in 
addition to EGFR activation by its ligand, EGF as well as that the drug cannot induce 
apoptosis in the majority of the cell lines (5 out of 7).  
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Figure 10: AEE788 does not induce cell death at physiological concentrations. 
Cells were incubated during four days with increasing concentrations of AEE788 
(0; 0.1; 1; 2; 5 and 10 µM). Apoptosis was measured by flow cytometry. 
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d. Patupilone 
Epothilones constitute a new class of microtubule-targeting compounds. One member 
of the epothilone family is patupilone, which has shown potent in vitro and in vivo antitumor 
activity (Altmann et al., 2000; Goodin et al., 2004). At nanomolar range, the drug exhibits 
taxol"-like properties and inhibits microtubule depolymerization, which potently inhibits the 
growth of human cancer cells in vitro. Since the function of the mitotic spindle is inhibited 
leading to mitotic arrest at the G2/M transition (Bollag et al., 1995; Altmann et al., 2000; 
Goodin et al., 2004). The anti-proliferative (Chou et al., 1998) and cytotoxic properties of the 
drug seem to be coupled to the disturbed mitotic spindle function (Blagosklonny & Fojo, 
1999) (Fig. 11). Microtubules have already been used as targets for a multitude of antimitotic 
drugs that have been used successfully in the treatment of cancer (Jordan & Wilson, 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 11: Mechanism of action of patupilone. 
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The effect of Patupilone was first analyzed on in vitro cell growth. Three glioma cell 
lines (LN71, LN229 and SF767), and one oligodendroglioma cell line (Hs683) carrying 
characterized mutations involved in glioma development were selected (Ishii et al., 1999). 
The effect of the drug on cell cycle profile was determined on glioma cell lines. All cell lines 
were tested using nanomolar concentrations of patupilone and exhibited a G2/M phase 
accumulation at a concentration as low as 0.7 nM (Fig. 12). This accumulation increased at 
higher concentrations of the drug indicating a dose-dependence. 
 
 
 
 
 
 
 
 
 
 
Changes of the microtubule network and of the shape of the nuclei were visualized 
with confocal laser microscopy. Prior patupilone treatment, the cells are large, showing 
variable shapes with filamentous staining, reflecting a high degree of organization of the 
microtubule system (Fig. 13a). After treatment with 5 nM patupilone much denser structures 
were formed with time, indicating an inhibition of depolymerization of the microtubule 
system already after 12hrs (c) of exposure to the drug. The microtubule network appeared 
damaged and shrunk and the nuclei became round after 12 hours (d). After 18h, the 
microtubules were still aggregated (e). 
 
Figure 12: Patupilone induces G2/M accumulation at low nanomolar 
concentrations. Four cell lines were treated for 18 hours either with vehicule 
DMSO alone or with increasing concentrations of Patupilone. Percentage of cells 
in G2/M phase was measured by flow cytometry. Data represent the average ± SD 
of 3 independent determinations.  
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The ability of the drug to induce apoptosis in glioma cells was analyzed. Various 
human glioma cell lines were treated with patupilone using increasing concentrations in the 
nanomolar range (Fig. 14). The drug caused 100 % apoptosis in all cell lines tested at a 35 nM 
concentration. At lower concentrations, the cell lines responded differently to the drug. No 
induction of apoptosis was observed at 0.05 nM in any of the cell lines. The drug was able to 
induce apoptosis already at 0.1 nM in LN229 and at 0.7 nM in the case of LN71 and SF767, 
Tubulin                        PI (40X) 
              NT 
12h 
18h 
Figure 13: Patupilone inhibits microtubules depolymerization. The microtubules 
were detected by confocal laser microscopy with tubulin antibody. LN229 cells were 
treated with 5 nM paputilone  for 18 hours. The pictures show the distribution of tubulin 
(a, c and e) and nucleus staining (b, d and f). Untreated control cells are shown in a and 
b. NT: no treatment 
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whereas more than 0.7 nM was needed in Hs683. However, LN401 was much more resistant 
to the drug and apoptosis was observed only at concentrations of 5 nM or higher. 
patupilone has demonstrated to cause cell death at a concentration as low as 0.1 nM in LN229 
and 100% of apoptosis was reached at a concentration of 35 nM after four days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e. Concluding remarks about single drug treatment 
Glioma cell lines were found to be insensitive at the tested concentrations of PKIs. 
Although 10 µM or higher concentrations of Gleevec were necessary to induce apoptosis, 
moderate concentrations of PKI-166 have been demonstrated to inhibit receptor activation, 
migration and proliferation. However, the treatment was not sufficient to induce apoptosis. 
AEE788, which also inhibits angiogenesis, didn’t either induce apoptosis. The question arises 
whether treatment with PKI alone is sufficient to induce apoptosis in glioma cells. While 
RTKi drugs such as Gefinitib or Gleevec have shown promising results on other tumor cell 
types, why is glioma still resistant to this kind of drugs? In contrast to PKIs, nanomolar 
concentrations of the cytotoxic compound patupilone were efficient in inducing apoptosis. 
Figure 14: Patupilone is highly toxic for glioma cells. Increasing concentrations of 
paputilone (0.05; 0.1; 0.7; 5 and 35 nM) were applied to different cell lines during four 
days of teatment. The percentage of viable cells was measured after four days using 
flow cytometry. Data represent the average ± SD of 3 independent determinations. 
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2. Combinatorial strategy 
 
a. Combination of RAD001, Gleevec and AEE788   
A major question is whether biologically active small drugs of the class of protein 
kinase inhibitors (PKIs) are sufficient to kill tumor cells (as proven by the paradigmatic 
Gleevec experience) or are combinations needed. Therefore, a basic question was addressed 
using an in vitro glioblastoma model. Combinations of Gleevec (0.5 µM), AEE788 (0.5 µM) 
and RAD001 (20 nM) have been tested for their capacity to induce apoptosis in glioblastoma 
cells highly resistant to cell death, either by biologicals alone as single or in combination. 
RAD001 is a derivate of the natural compound rapamycin that induces G1 growth 
arrest in yeast, Drosophila, and mammalian cells. Genetic and biochemical studies have 
established that the target of rapamycin is the protein kinase mTOR. In vivo experiments were 
done in nude mice xenografts. CCI-779, another analogue of rapamycin - when given for five 
consecutive days - inhibited glioblastoma tumor growth for up to two weeks after drug 
withdrawal, whereas normal immune function was restored as early as one day following 
withdrawal, indicating that an intermittent dosage of CCI-779 could be effective (Gibbons et 
al., 1999). Thus, RAD001 may be a promising therapeutic agent for the treatment of cancers 
in which a dysregulation of the PI3K pathway is involved.  
Each compound targets critical pathways in gliomagenesis (Fig. 15). We looked for 
additive and/or synergistic effects in order to limit toxicity and lack of specificity of these 
drugs, concentrations were selected according to the results obtained by the use of single 
drugs that means 20 nM for RAD001 and 0.5 µM for AEE788 and Gleevec. 
We intended to correlate the induction of apoptosis by the drugs with the genetic 
status of the PTEN/p53/p16INK/p14ARF genes. To do so, various cell lines were selected based 
on their respective genetic backgrounds for these genes (Annex IV). Therefore, a larger panel 
of genetically well-defined tumor lines has been tested for their proliferative, invasive and 
pro-apoptotic properties upon exposure to these drugs as single agents and in various 
combinations. Cells were incubated with single drugs and in combinations. A 
phenomenological classification of cell lines according to similar patterns of the response to 
the drugs has been established (Fig.16). 
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The cell lines that turned out to be resistant to all kind of treatments, represented the 
first group (LN401, LN71, LN229 and LN319) (Fig. 16a). The second group (LN18, LN215 
and SF767) featured a specific sensitivity to AEE788, to which combination with Gleevec 
resulted in an additive induction of apoptosis. While RAD001 had no effect on LN18 cell 
death, RAD001 enhanced the cytotoxic effect induced by AEE788 in LN215, and RAD001 
reduced the cytotoxic effect caused by AEE788 in SF767. The last group of cell lines, Hs683, 
U373 and U343, showed a cytostatic response to each one of the drugs. The basal level of 
apoptosis is reduced in all the combinations tested (Fig. 16c). 
 
 
Fig. 15: Major signaling pathways in gliomas. The PKIs Gleevec, AEE788, PKI-
166, RAD001 and the cytotoxic drug patupilone are shown together with their 
molecular targets. 
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All these results obtained by combinations of the three biologicals are summarized in 
Figure 17. In addition to the apoptosis data, the genetic status of the PTEN/p53/p16INK/p14ARF 
genes in GBM was added in order to correlate them with the apoptosis results. In conclusion, 
neither single drugs nor double and triple combinations caused substantial levels of apoptosis. 
Only in SF767 and LN215 (second group), combination of drugs led to 30% of apoptosis at 
best. 
Figure 16: Induction of apoptosis by the various PKIs alone or in 
combination. Cell lines were incubated with the drug(s) during 4 days. 
Percentage of dead cells was measured by flow cytometry. Data represent the 
average and standard deviation of 3 independent experiments. NT: no treatment, 
AEE: AEE788 (0.5 µM), Rad: RAD001 (20 nM) and Gleevec (0.5 µM). 
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b. AEE788 and Patupilone 
All drugs alone or in combination tested so far gave either no substantial induction of 
apoptosis or exhibited cytotoxicity when used at concentrations inducing apoptosis 
(patupilone). We then investigated whether a combination of the most promising biological, 
AEE788, and subcytotoxic concentrations of patupilone could lead to a synergistic induction 
of cell death. 
As shown in Fig. 8a, treatment of the cell lines with AEE788 alone at 1 µM 
concentration led to a complete block of EGFR activation. Addition of EGF was able to 
activate EGFR phosphorylation, whereas pretreatment with the drug blocked the activation in 
a dose dependent manner. However, this concentration did not induce apoptosis (Fig. 10). A 
combinational treatment has been performed using 1 µM AEE788 with increasing 
concentrations of patupilone (Fig. 18a). Both drugs caused apoptosis in a synergistic manner 
in LN71, SF767 and LN401. In contrast, only an additive effect was observed in U373, 
LN215, and only a slight effect in Hs683 and LN229. In addition, the determination of the 
concentration necessary to induce 50% of apoptosis (“AC50” modified IC50 for apoptosis 
instead of proliferation) of the AEE788/ Patupilone combination revealed that AEE788 acted 
as a sensitizer in all the cell lines (Fig. 18b). AEE788 alone gave “AC50” values in the 
micromolar range (LN71: 5.5, LN215: 5.1, SF767: 4.9 and LN229: 5.5) while “AC50” of 
Hs683, U373 and LN401 could not be determined since the drug, even when combined, did 
not reach 50% of apoptosis at these defined subcytotoxic concentrations. patupilone induced 
apoptosis at a concentration in the nanomolar range. In combination, AEE788 decreased the 
“AC50” values in all cell lines at a lower induction of apoptosis in cell lines such as LN229 
and Hs683 than in the other cell lines where an additive or synergistic induction of apoptosis 
was observed. 
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The synergistic induction of apoptosis occurred in LN71, LN401 and SF767 cell lines 
at concentrations between 0.05 and 0.1 nM, that is in a range where both drugs were not 
effective when they were used alone. The lowering of the dosage of paputilone has the 
advantage that also its toxicity is reduced. This result indicated that the specific combination 
of these two drugs led to a strong potentiation of their ability to induce apoptosis in some of 
the glioma cell lines. 
 
c. Conclusion about drug combinations 
Taken together, the data obtained from single as well as combined drugs demonstrated 
that the glioma cell lines exhibited a wide spectrum of resistance. On one hand, the triple 
combination (Gleevec, AEE788 and RAD001) was not able to induce a high level of 
apoptosis, on the other hand the combination between paputilone and AEE788 revealed that a 
synergistic effect was obtained at low nanomolar range by double treatment, but only in 50% 
of the cell lines treated. 
 
3. Resistance of glioma cells towards drug treatment 
 
a. Introductory questions 
Why were the PKIs alone or in combination drugs rarely efficient in the induction of 
apoptosis? What are the reasons for the low sensitivity? How can the low sensitivity be 
overcome? In this context, we investigated a possible correlation between induction of 
apoptosis and the genetic status of EGFR, PTEN, p53 and p16INK4A/p14ARF and/or basal 
expression levels of specific proteins like e.g. ErbB receptors and others. 
 
b. Comparison of the genetic status of EGFR-PTEN-p53-p16/p14 of the cell lines 
and their sensitivity to the drugs 
Of note, although some cell lines showed similar genetic status regarding glioma 
genes, they responded differently to the various treatments, for example, Hs683 and LN229, 
which are both wild type for PTEN. Similarly, LN215 and U373 both harbour deletions at the 
p16/p14 locus; while LN401 and LN71, which both have the same genetic status for PTEN, 
p53 and p16/p14 genes (Annex IV) and LN71 and SF767 exhibited similar EGFR RNA 
expression (Fig. 19a). There was no obvious correlation between the status of these four 
genes and the drug resistance of the respective cell lines. 
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c. Comparison of various protein levels of the cell lines and their sensitivity to the 
drugs 
With respect to their importance in gliomagenesis, levels of PTEN or ErbB receptors 
were measured. Phosphorylated AKT and ERK, components of the PI3K/Akt and 
Ras/Raf/MEK/ERK signaling cascades, shown to play a critical role in gliomagenesis (Maher 
et al., 2001), have also been tested. 
 
 
                    
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Basal expression of specific proteins of cell lines. (A) EGFR/ErbB1 
gene expression using RT-PCR is also shown. (B) Expression levels of proteins 
potentially involved in gliomagenesis determined by Western blot analysis.  
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Interestingly, although LN71 and SF767 exhibited similar EGFR protein levels, the 
induction of apoptosis appeared to be different. The efficacy of EGFR inhibitors on 
proliferation, migration and receptor activation does not correlate with the degree of 
overexpression of EGFR or ErbB2 (Fig. 10 and 19b). Then, expression of other biomarkers of 
the drug was also analyzed, including VEGFR-2 (KDR), ErbB3, ErbB4 which showed a high 
level of variation of proteins levels. Basal ERK1/2 activities were also found to be high in all 
the cell lines, excepted in SF767, where no ERK1 (p44) activity was detected. Finally, several 
cell lines tested overexpressed phosphorylated AKT (P-AKT) mainly due to the PTEN 
deletion, and all displayed high level of phosphorylated ERK. 
 
d. De-activation of AKT and/or ERK as readout for treatment of GBM cells 
Simultaneous constitutive activation of Akt and Ras has been shown to induce 
gliomagenesis in transgenic mice (Holland et al., 2000). Similarly, activation of both Akt and 
Ras combined with Ink4a/Arf knock out in mice also develop gliomas (Uhrbom et al., 2005) 
(Annex I). Based on the results of these in vivo experiments, we intended to use AKT and 
ERK as readout for the induction of glioma cell death. 
Two cell lines (U373 and SF767) exhibiting different levels of apoptosis at the 
concentrations used were selected (Fig. 20). Cells were treated with either 1 or 10 µM of 
AEE788 to investigate induction of apoptosis and ERK/AKT activities at 1, 8 and 24 hours.  
In U373 treated with 1 µM AEE788, no change in the phosphorylation status of AKT and 
ERK was observed, despite blocking of the EGF receptor activation, and no apoptosis was 
detected. In contrast, SF767 treated with 1 µM AEE788 had inhibition of AKT and ERK 
activities as early as one hour after treatment and showed apoptosis. At 10 µM concentration, 
in both cell lines AKT and ERK activities were partially (U373) or completely (SF767) 
inhibited after twenty-four hours, in parallel to the induction of apoptosis (Fig. 20). Thus, 
SF767 showed the highest sensitivity to AEE788 with respect to inhibition of both ERK and 
AKT activities and apoptosis levels obtained in these conditions (Fig. 20). From these results, 
the hypothesis evolved that drug resistance in U373 was due to the high level of 
phosphorylation of ERK and/or AKT. In order to test this hypothesis, the PI3K inhibitor 
wortmannin and the MEK inhibitor U0126 were used (Fig. 21a) to completely abrogate AKT 
or ERK activation. 
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In order to investigate the pathways involved in the glioma tumor lines, cell lines were 
treated with each compound individually and in combination (Fig. 21b). Drugs alone, except 
U0126, did not induce apoptosis. The MEK inhibitor (U0126) induced apoptosis in 45% of 
LN215. Interestingly, an increased induction of apoptosis was observed for several drug 
combinations: AEE788 plus wortmannin led to 42% apoptosis in SF767, AEE788 and U0126 
to 41% in LN71 and to 54% in LN215. In fact, the combination of U0126 and wortmannin 
appeared to be most efficient to trigger cell death. The frequency of apoptotic cell population 
resulting from the individual drug treatments provided a baseline for evaluating whether drug 
combinations may act in an additive or in a synergistic manner. Thus, by killing 33% of 
LN401, 41% of Hs683 and 73% of LN215, we could establish that the combination of U0126 
and wortmannin acted in an additive way, while U0126 and wortmannin synergized to induce 
apoptosis in 58% of LN71 and in 75% LN229. 
 
 
Figure 20: Inactivation of ERK and AKT activities by AEE788. Cells were 
incubated with 1 or 10 µM of AEE788. To determine the potential correlation between 
induction of apoptosis and protein inhibitions, drug effects were observed during 24 
hours. Level of proteins and respective activities were determined using the following 
antibodies. PY: anti-phosphotyrosine, P-AKT: Ser 473 of AKT and P-ERK: ERK1/2 
activities.  
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Figure 21: Synergistic induction of apoptosis by wortmannin and U0126. (A) Signaling 
pathways targeted by U0126 and wortmannin. (B) Induction of apoptosis of U0126, wortmannin 
and AEE788 alone or in combination. Combination of AEE788 in presence or absence of the MEK 
inhibitor and/or the PI3K inhibitor can induce a synergistic induction of apoptosis.  U0126 and 
wortmannin were added every day whereas AEE788 only once at day 0. Apoptosis was measured 
after 4 days of treatment and experiments were made in triplicates. Percentage of apoptosis was 
determined by flow cytometer.  
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In response to a given combination, cell lines showed quite constant levels of 
apoptosis. Indeed, combination of U0126 and wortmannin was efficient in 6 out of 7 cell lines 
and the triple combination of AEE788, wortmannin and U0126 caused more than 50% of 
apoptosis in 6 out of 7 cell lines. These results supported the hypothesis that the AKT- and 
ERK- related pathways may serve as potential targets in glioblastoma treatment. However, 
some cell lines such as U373 and LN401 were resistant to combined treatment. The nature of 
the resistance was further investigated. 
Abrogation of ERK and AKT activities was determined upon single and combinatorial 
treatments. After one hour, wortmannin and U0126 inhibited the phosphorylation of AKT and 
ERK in all the cell lines tested (Fig. 22). Nevertheless, as shown in parallel FACS analysis 4 
days after drug treatment, these cell lines showed diverse apoptotic reponses despite the fact 
that the combination between both inhibitors completely abrogated both ERK and AKT 
activities (Fig. 22). 
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Figure 22: Wortmannin and U0126 inhibit their respective biomarkers. 
After one hour, both compounds inhibit ERK and AKT activities at the 
concentrations selected. CT: control, A: AEE788 (1 µM), U: U0126 (20 µM), 
W: wortmannin (1 µM). After treatment, SDS was added and western analysis 
was performed. 
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e. Simultaneous inhibition of both AKT and ERK activities is needed to induce cell 
death 
To test the hypothesis that inhibition of both AKT and ERK activations are needed to 
induce glioma cell death, the phosphorylation status of both proteins was determined after 72 
hours drug treatment, in parallel to the apoptosis assay performed after 96h, as described 
above (Fig. 18 and 22).  
When compounds, AEE788 and Paputilone, were combined, only LN71 and SF767 
showed an inhibition of phosphorylation of both ERK1/2 and AKT after 24 and 72 hours 
whereas LN229 and Hs683 still exhibited strong phosphorylation of both kinases (Fig. 23a). 
When compared to the apoptosis data shown above (Fig. 18a), these results indicate a 
possible correlation between the simultaneous inhibition of both pathways and induction of 
apoptosis. 
In order to test this hypothesis in a new context, the activities of AKT and ERK were 
specifically inhibited by wortmannin and U0126 (Fig. 23b). The cells were treated with single 
or with combined drugs and the phosphorylation status was defined after 72 hours. In 
response to U0126 and wortmannin, ERK and AKT were no longer phosphorylated in 3 of 
the 6 cell lines (LN215, LN229 and SF767). This simultaneous inhibition correlated with the 
additive or the synergistic induction of apoptosis observed previously (Fig. 21). These results 
have to be compared with those presented in Fig. 21. SF767 exhibited a full decrease of P-
AKT under the same conditions, while LN229 and LN215 showed a less pronounced effect. 
In contrast, cell lines with high levels of P-AKT (i.e PTEN -/- cells such as U373 and LN401) 
or sustained ERK activity such as U373, LN401 and Hs683 demonstrated to be more resistant 
and exhibited sustained signal of P-ERK and P-AKT. Thus, these results are in agreement 
with the additive or the synergistic induction of apoptosis of these drugs observed in the same 
cell lines (Fig. 21).  
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f. Restoration of ERK activity abrogated the pro-apoptotic effect of U0126 
In contrast to wortmannin, U0126 alone was sufficient to induce apoptosis (Fig. 21). 
In order to test the hypothesis that sustained activity of ERK should increase cell survival, the 
Figure 23: Combination of AEE788 and paputilone or U0126 and wortmannin can 
result in the inhibition of both phosphorylated AKT and ERK. (A) Cells were 
incubated during three days with Paputilone (0.7 nM) with or without AEE788 (1 µM). 
SDS was added at the indicated time and a western analysis was performed. (B) Cell lines 
were treated either with U0126 (20 µM) or wortmannin (1 µM) or in combination. After 
three days of treatment, SDS was added and western analysis was performed. NT: no 
treatment. A: AEE788, U: U0126, P: Patupilone, W: wortmannin. 
A 
B 
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phorbol ester TPA was used. This compound is activating PKC and ERK1/2 thereby 
modifying mitogenic signaling pathways (Crews et al., 1992; Lang et al., 1994).  
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When exposed to 20 nM TPA, LN71, LN215, LN229 and Hs683 cells showed strong 
increase of phosphorylated ERK levels (Fig. 24).  
In order to test a possible correlation between decreased phosphorylation of ERK and 
apoptosis, we selected the LN71 cell line because of its strong induction of apoptosis by the 
use of the combination of AEE788 and paputilone. LN71 was treated with AEE788 and 
Patupilone in presence or absence of TPA (20 and 100 nM) as described above (Fig. 25a). As 
expected, the combination of AEE788 and Paputilone induced apoptosis in a synergistic 
manner (Fig 18a), whereas the addition of TPA protected the cells from apoptosis. Higher 
activities of ERK1/2 were detected upon TPA treatment compared to the drug combination 
alone (Fig. 25b). Using the same protocol, cell lines were treated with the U0126 and 
wortmannin for 4 days in presence or absence of TPA (20 or 100 nM) (Fig. 25c). As 
described for AEE788 and patupilone, addition of 20 nM TPA reduced the fraction of cells 
undergoing apoptosis in response to U0126 and wortmannin. This correlated with the 
increased levels of ERK1/2 activation whereas in contrast to ERK, inhibition of 
phosphorylated AKT did not correlate with induction of apoptosis (Fig. 25d). 
Although activition of ERK1/2 seemed to have a dominant effect over that of AKT 
(Fig. 25d) on apoptosis, cell lines such as LN215 retained high phosporylation levels of both 
proteins, even when the apoptosis level was reduced (Fig. 25c and d). It remained therefore 
unclear whether complete inhibition of AKT activity is required for the induction of 
apoptosis. Comparison of basal P-AKT levels before and after treatment revealed that partial 
or full reduction of P-AKT levels were associated with cell death (LN71, LN229 and Hs683) 
Figure 24: Activation of ERK in glioma cell lines by TPA. ERK activation in cell 
extracts was determined by western analysis. Cells were treated either with 20 or 
100 nM of TPA during 30 min.  
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(Fig. 25) but this was not the case with U373 and LN401 (Fig. 23). In contrast, in LN215 
apoptosis occurred at higher level of AKT phosphorylation than in the control. 
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g. Drug responsiveness is cell line-dependent 
 
 
A 
D 
B 
C 
Figure 25: Addition of TPA caused a decrease in the induction of apoptosis by the 
drugs. (A) AEE788 and patupilone combination in presence or absence of TPA. In 
contrast to AEE788 and Paputilone, TPA was added every day. Cells were treated during 
4 days prior to FACs analysis. (B) Correlation between protein activities and apoptosis of 
the AEE788 and paputilone combination. Cells were treated during 3 days prior to 
western analysis. (C) As described in (A) but with the combination of U0126 and 
wortmannin. (D) As described in (B) but with the U0126 and wortmannin combination. 
U: U0126 (20 µM), W: wortmannin (1 µM), A: AEE788 (1 µM) and P: paputilone (0.7 
nM). Cells were treated during 3 days. After incubation, cell extracts were prepared by the 
addition of SDS sample buffer.  
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In order to further confirm the possible correlation of induction of apoptosis and low 
levels of AKT and ERK activities, induction of apoptosis was investigated with cell lines 
resistant to the AEE788/paputilone combination, for this purpose, LN229 and Hs683 cells 
were selected (Fig. 18a). Addition of either wortmannin (PI3K inhibitor) or U0126 (MEK 
inhibitor) should reveal which of these two protein kinase activities are critical for the 
induction of apoptosis (Fig. 26a). Addition of the two inhibitors caused induction of 
apoptosis. In LN229, the level of apoptosis induced by the inhibitors are only additive 
whereas in Hs683, an additive induction of apoptosis was observed with U0126 or synergy 
with wortmannin. Interestingly, the various cell lines responded in completely different ways 
to the two inhibitors. In contrast to LN229, Hs683 exhibited a higher sensitivity to the PI3K 
inhibitor than to the MEK inhibitor.  
Whereas the triple combination of AEE788, U0126 and wortmannin induced 95 and 
70% of apoptosis in LN229 and Hs683 (Fig. 22), respectively the addition of either U0126 or 
wortmannin to the AEE788 plus Patupilone only led to 30 to 40% of apoptosis in LN229 and 
Hs683. Western analysis of extracts from cells treated by these combinations was performed 
at the same time. While inhibition of both protein activities led to induction of high levels of 
apoptosis (compare Fig. 18a /23a and Fig. 21b/23b), a partial reduction of signaling only led 
to apoptosis in a fraction of the cell population ranging from 30 to 40% (Fig. 26a and b).  
These results indicated that targeting either one of the kinases only partially sensitizes 
the cells to drug treatment (Fig. 26a). Only when both kinase activities are inhibited 
simultaneously high levels of apoptosis are induced. Taken together, the results suggest that 
the strong induction of apoptosis, by the two drugs is due to the inhibition of both protein 
kinases, ERK1/2 and AKT. Cell lines that were more resistant to the drug combination 
exhibited remaining activities of one or both kinases. 
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A 
B 
Figure 26: Induction of apoptosis by targeting either ERK or AKT activity. (A) LN229 
or Hs683 were treated with AEE788 (1 µM) and Patupilone (0.7 nM) in combination either 
with U0126 (20 µM) or wortmannin  (1 µM) during 4 days. (B) Western analysis was 
performed in order to determine the relative activities of ERK1/2 and AKT after 3 days of 
treatment. U: U0126, A: AEE788, W: wortmannin, P: patupilone. (*) Results from a 
previous experiment (Fig. 21). 
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Discussion 
 
Although surgical resection, radiotherapy and chemotherapy can significantly improve 
the prognosis of patients with breast, lung or prostate cancers, these therapies remain of 
limited efficacy in the treatment of GBM. Progress made in molecular neuro-oncology has 
established that the PDGF and EGF pathways via PI3K/Akt and Ras/Raf/MEK/ERK 
signaling cascades play a critical role in gliomagenesis (Maher et al., 2001). Accumulation of 
genetic alterations in these pathways confers a growth advantage to transformed cells leading 
to uncontrolled cell proliferation, high potential of invasion and drug resistance. Thus, 
identification of the altered signaling mediators allows the designation of potential molecular 
targets for isolating novel anti-tumor compounds. The epidermal growth factor receptor 
(EGFR) had been designated early as a major target for anti-tumoral drug screening for 
glioma, breast and NSCL cancer therapy (Annex III). The purpose of this work was to study 
drugs targeting EGFR and other signaling mediators for the treatment of gliomas and to 
define factors that allow induction of apoptosis in response to these anti-tumoral drugs in 
GBM cells in an in vitro cellular system. 
 
Targeted strategies: the problem of cross-talk 
 The process of cellular signal transduction has been viewed for a long time as a linear 
cascade of successive events of activation and/or inhibition. Interconnections between distinct 
signaling cascades, designated cross-talk, provide a possible explanation on how inhibition of 
specific proteins can be circumvented through alternative pathways, as depicted in Fig. 27.  
Treatment should not only consider the capability of AEE788 to block EGFR 
activation, but also the inhibition of molecular events that occur downstream of EGFR 
signaling. For example, many GBM cells carry PTEN mutations activating AKT/PKB. In this 
scenario, inhibition of RTK activation cannot be sufficient if downstream signaling 
components remain activated, thereby providing an explanation for the resistance of cell line 
U373 in the combination of AEE788 and patupilone at the concentrations tested. For this 
reason, drugs designed to target components located downstream of EGF signaling, such as 
MEK, would be better strategic choices for specifically acting on this pathway. This may be 
superior to targeting EGFR itself. 
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 A ubiquitous mechanism of resistance of tumor cells to intracellular drugs is related to 
the alterations of drug transport and efflux by the P-glycoprotein (P-gp) family of membrane 
transporters: P-gp, being the product of the multidrug-resistance gene mdr1 (Schinkel et al., 
1994). On the other hand, the ABC (ATP-binding cassette) transporter P-glycoprotein (Pgp) 
has been demonstrated as a key element of the blood-brain barrier (BBB) that can actively 
transport a wide variety of lipophilic drugs out of the brain capillary endothelial cells that 
form the BBB. In addition to Pgp, other ABC efflux transporters such as members of the 
multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem 
to contribute to BBB function. Consequences of ABC efflux transporters in the BBB include 
minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate 
into the brain. However, ABC efflux transporters may also limit the central distribution of 
drugs that are beneficial to treat CNS diseases (Loscher& Potschka, 2005). 
 In this context, the tumor resistance seen in EGFR targeted therapies can be attributed to 
the following reasons (Fig. 28): 
(a) The simultaneous activation of tyrosine kinase receptors such as insulin-like 
growth factor receptor I (IGFR-I) or PDGFR. In glioma cell lines, inhibition of AKT/PKB 
activation is counteracted by sustained PI3K activation by IGFR-I (Chakravarti et al., 2002).  
Figure 27: Linear and non-linear signaling pathways. EGFR, IGFR-I 
and PDGFR represent the upstream component whereas downstream 
components (o) lead to the activation or inhibition of the effectors (E).  
non-linear
(cross-talk)
E E E
EGFR  IGFR-I   PDGFR
o o o
o o o
linear
E E E
o o o
o o o
EGFR  IGFR-I   PDGFR
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(b) The existence of specific EGFR mutations. In contrast to NSCLC, where tumors 
with mutations at the EGFR kinase domain showed increased responsiveness to gefinitib 
(Sordella et al., 2004), no EGFR mutations were observed in glioma lines (Barber et al., 
2005) providing an argument on the resistance of gliomas to anti-EGFR drugs.  
(c) The constitutive activation of downstream mediators. Deletion of PTEN, which is 
highly prevalent in gliomas, upregulates AKT and counteracts ErbB1/2 inhibition by 
preventing apoptosis. 
 
Gleevec and blast crisis: analogy with GBM treatment 
The designation of a target for anti-tumoral drug screening must be based on its role in 
tumor induction. A famous example is provided by Gleevec, a compound used for chronic 
myeloid leukemia (CML) treatment. CML results from the Philadelphia chromosome 
translocation. This translocation generates a chimaeric BCR-ABL protein fusion that renders 
the tyrosine kinase of the proto-oncogene ABL constitutively active (Sawyers, 1999), and 
subsequently causes the malignant transformation. For this reason, it turned out to be a target 
of choice for drug screening (Daley et al., and Lugo et al., 1990). Gleevec was the first 
selective protein kinase inhibitor developed for targeted cancer therapies and treatment as a 
single agent has demonstrated remarkable clinical efficacy in CML, except at the blast crisis 
stage (Drucker, 2004) where mechanisms of resistance to Gleevec occur. Either BCR–ABL is 
reactivated through mutation(s) in the ABL kinase domain (Gorre et al., 2001), or secondary 
tyrosine kinases of alternative signaling pathways become activated (Hingorani et al., 2003). 
Thus, these genetic modifications render Gleevec alone insufficient to counteract the 
tumorigenic effect produced by other signaling pathways. In contrast, EGFR alone, although 
overexpressed in gliomas, cannot induce glioma formation in mouse models (Bachoo et al., 
2002). Retrospectively, it is not surprising that targeting of EGFR by AEE788 alone does not 
induce cytotoxicity in glioma cells. 
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Mouse brain models used: definition of new targets 
Analyses of transgenic mouse models have established that gliomagenesis can be 
initiated from a specific combination of genetic alterations of AKT and RAS. Therefore, one 
can expect that molecular therapies targeting both pathways might be more successful than 
those disrupting the function of only a single pathway.  
One other example is EGFR. EGFR gene amplification has been associated with poor 
prognosis for GBM patients (Nicholson et al., 2001). New small molecular weight 
compounds such as PKI-166 or AEE788 have been generated to target EGFR. In this study, 
we used the two drugs to target EGFR in GBM cells. As it was defined in EGFR transgenic 
and Ink4a/Arf KO mice (Holland et al., 1998) and in orthotopically transplanted brain tumor 
models (Bachoo et al., 2002), activated EGFR cooperates with inactivation of Ink4a/Arf to 
induce glioma-like lesions. In fact, inactivation of both p16INK4a and p19Arf genes in 
cooperation with activated EGFR is of importance for the development of astrocytic tumors.  
If two pathways have to be altered to develop a glioma in a mouse, we conclude that 
at least two pathways need to be targeted for treatment in humans, too. Among the seven 
glioma cell lines with defined genetic background for glioma genes (Ishii et al., 1999) we had 
analyzed, six displayed expression of activated EGFR and four were Ink4a/Arf -/-. We 
therefore considered these four latter cell lines to be suitable for testing EGFR as a drug target 
and the other ones as negative controls. Consistent with our hypothesis, SF767 and LN215 
lines, both wild-type for Ink4a/Arf, were sensitive to AEE788. Conversely, GBM lines with 
activated EGFR together with a homozygous deletion at the Ink4a/Arf locus did not respond 
at all to AEE788.  
 
Targeted combinations against EGFR, PDGFR and mTOR do not induce apoptosis 
 We have shown that AEE788 treatment induces little to no apoptosis in the cell lines 
U373 and LN401, in a similar manner as other PKI e.g. Gleevec is targeting overexpressed 
PDGFR in glioma (Hermanson et al., 1992). Single targeting of RTKs did not show induction 
of apoptosis in GBM lines, according to the hypothesis on the necessity to hit two distinct 
glioma pathways. Consequently, we combined the anti-EGFR drug AEE788 and the anti-
PDGFR drug Gleevec for glioma treatment. However, this combination did not lead to 
apoptosis. Retrospectively, this is consistent with the redundancy between both RTKs 
signaling pathways, and with the fact that overexpression of both EGFR and PDFDR may not 
 56 
be sufficient to induce gliomagenesis.  
 Next, we performed the triple combination consisting of targeting the putative growth 
factor pathways (EGFR and PDGFR), together with the downstream component of the 
PI3K/Akt pathway –mTOR- that regulates cell growth (Inoki et al., 2005). It turned out that 
application of AEE788, Gleevec and RAD001 resulted in a very modest induction of 
apoptosis in 3 out of 10 GBM cell lines. This is consistent with our hypothesis that EGFR, 
PDGFR and mTOR may be not critical to maintain the neoplastic phenotype in these GBM 
cells. 
On the other hand, the results obtained by treating GBM cell lines with AEE788 have 
confirmed EGFR as a promoter of glioma cell proliferation and migration. In addition, 
AEE788 also targets the pro-angiogenic receptor KDR (VEGFR-2) with a high specificity 
(IC50=77 nM) (Traxler et al., 2004), although KDR inhibiton has not been established in vivo 
mouse xenogragft model. Interestingly, other in vivo data have shown AEE788 to increase 
survival of animals with intracranial tumor at concentration below the maximally tolerated 
dose (Goudar et al., 2005) and confirmed a potential role of AEE788 as anti-tumor agent. 
 
Combination of PKIs with a cytotoxic compound leads to a synergistic induction of apoptosis  
 Altogether, these results obtained with AEE788, Gleevec and RAD001 alone or 
combined did not induce tumor cell death in vitro. We intended to associate AEE788 with the 
highly cytotoxic compound Paputoline, in order to sensitize glioma cells to apoptosis.  
Patupilone is a microtubule-targeting compound. Microtubules (MTs) are key 
components of the cytoskeleton, They are not only crucial for the development and the 
maintenance of cell shape, in the transport of vesicles, mitochondria and other components 
throughout cells, in cell signalling, but essential in cell division and mitosis. Moreover, a 
body of evidence suggests that aneuploidy is often caused by a particular type of genetic 
instability, called chromosomal instability, which may reflect defects in mitotic segregation in 
cancer cells (Rajagopalan & Lengauer, 2004). For these reasons, MTs have been designated 
as critical targets for anticancer drugs (Jordan & Wilson, 2004). 
Patupilone exhibits in vitro cytotoxic properties on tumor cell lines of various 
lineages, including multi-drug resistance (MDR) cell lines (Chou et al., 1998). Patupilone 
treatment revealed potent in vivo antitumor activity (Altmann et al., 2000). However, mice 
exhibited loss of body weight, followed by death (Chou et al., 1998) and clinical trials 
revealed very strong side effects (Diarrhea, fatigue, nausea and vomiting) (Goodin et al., 
 57 
2004). From the results obtained in the glioma cell lines tested, patupilone appeared to be 
efficient as low as at a nanomolar range. When exposed to patupilone at a concentration of 35 
nM concentration, no glioma cell line tested showed resistance to apoptosis which render this 
compound much more efficient than PKI in the induction of apoptosis. The question is 
whether even lower concentrations of the drug, leading to a reduction of the side effects, 
would exhibit the same ability to induce apoptosis when used in combination with AEE788. 
Indeed, AEE788 has been shown to act as an anti-proliferative, anti-migratory and anti-
angiogenic compound (Traxler et al., 2004). Interestingly, we detected a synergistic induction 
of apoptosis in glioma cell lines when we combined AEE788 and Patupilone using 
concentrations that do not induce cell death when the two drugs are applied alone. This 
synergy occurred in LN71 and SF767 and slightly in LN229, U373 and Hs683 at picomolar 
range concentrations of patupilone (between 0.1 and 0.7 nM), whereas an additive effect was 
observed in LN401 and LN215. Evaluation of the concentration where 50% of apoptosis was 
reached (AC50) demonstrated the strong potentiation of AEE788 (1 µM) to act as sensitizer in 
these GBM cell lines (Fig. 27). 
 
Targeting downstream components of the EGFR signaling pathways induces glioma cell 
death 
According to results shown in Fig. 18, the combination between AEE788 and 
Patupilone leads to non-additive, additive or synergistic effects. What are the reasons why 
synergistic induction of apoptosis was not observed in all lines, while low effect was found in 
other cell lines. MEK kinase 1 (MEKK1) has been reported to transduce c-Jun NH2-terminal 
kinase activation in response to changes in the microtubule cytoskeleton of mouse embryonic 
stem cells thereby protecting the cells from apoptosis (Yujiri et al., 1998). c-Jun NH2-
terminal kinase activation upon drug treatment may explain the induction of this synergy. 
However, when we treated the glioma cells with the taxol-like microtubule toxin  patupilone, 
the JNK pathway was not affected in none of the glioma cell lines, regardless of their 
respective sensitivities towards the drug with respect to induction of apoptosis (data not 
shown). Besides the fact that our analysis has been performed with different and transformed 
cell types, we have measured JNK activation at much later time points namely at 24 and 72 
hours. It appears that MEKK1-JNK pathway was not involved in the sensitivity to the drug.  
Next, we analyzed whether constitutive activation of downstream mediators may lead 
to drug resistance, counteracting the effect of the EGFR inhibitor by maintaining activated 
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downstream regulators involved in survival or proliferation which could explain the 
inefficacy of targeted EGFR therapies in some cell lines. Downstream cascades of EGFR are 
the Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways.  
With regard to glioma animal models, transgenic mice developed gliomas with 
activated Ras and Akt (Holland et al., 2000) or associated with the deletion of Ink4a/Arf locus 
(Uhrbom et al., 2002), whereas single activated Ras or Akt failed to induce tumor formation. 
Altogether, these data argue for an involvement of AKT and ERK in the synergistic induction 
of anti-apoptotic signaling. This argumentation was confirmed in our AEE788-
PATUPILONE combination: inhibition of their activities could explain the synergistic 
induction of apoptosis observed in the AEE788 and patupilone combination. We have 
demonstrated that a very strong downregulation of phosphorylation of both AKT and ERK1/2 
occurs in the cells that show this synergy upon co-treatment with AEE788 and patupilone. 
This result suggests that induction of apoptosis requires the combined/simultaneous down 
regulation of both downstream signaling pathways of EGFR.  
 
Inactivating AKT/PKB and ERK: a new strategy for glioblastoma 
 Efficacy of novel drug therapies should not only take into consideration the ability to 
block EGFR activation, but should also be tested for their potential to inactivate downstream 
signaling mediators. This idea is further supported by in vitro experiments, where 
downregulation of ERK and AKT signals correlates with induction of apoptosis by activation 
of the pro-apoptotic protein Bad (Ellert-Miklaszewska et al., 2004).  
We have shown that inhibition of AKT and ERK was not necessarily dependent upon 
EGFR activity. In addition, mouse models have shown that activation of both pathways is 
needed for tumor induction (Holland et al., 1998 & Bachoo et al., 2002). One exception is the 
transgenic mouse model reported by Ding et al., (2001) in which activated Ras gene alone can 
promote growth of malignant human astrocytomas and exhibit genetic instability. 
Nevertheless, whether high levels of Ras-GTP are responsible for this genetic instability or 
whether this is simply due to other genetic alterations remains to be clarified. 
In this context, we aimed to specifically inactivate the two main effectors in the 
Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways, namely ERK and AKT by targeting 
MEK and PI3K with inhibitors. Consistently, the use of protein kinase inhibitors known to 
downregulate AKT and ERK activity confirmed our hypothesis about the need to target these 
two distinct signaling pathways.  
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The combination of these inhibitors was efficient in 6 out of 7 cell lines tested. Our 
experiments demonstrate that biologically based therapies, which target two components 
within complex signaling cascades, may effectively cooperate in the preclinical treatment of 
brain cancer.  
Basically, we have demonstrated that dual inhibition of PI3K by wortmannin and 
ERK by the MEK inhibitor (U0126) results in a high induction of apoptosis in glioma cell 
lines. In addition to inhibition of PI3K, wortmannin inhibits myosin light chain kinase, 
phospholipases C, D andA2, and DNA-dependent protein kinase (West et al., 2002). Lack of 
specificity of wortmannin may be taken into consideration since the PI3K related kinases 
(PIKKs) comprise a family of proteins that play central roles in the control of cell growth, 
gene expression, genome surveillance and repair in eukaryotic cells. Mammalian cells express 
six PIKK family members, five of which-ATM, ATR, mTOR, DNA-PK, and hSMG-1-
function as protein serine-threosine kinases (Abraham, 2004). U0126 inhibits 25 other protein 
kinases (Cohen, 1999), interleukin-2 synthesis and T cell proliferation (DeSilva et al., 1999). 
In addition to their lack of specificity, both are only soluble in organic solvents, which limits 
their clinical application. Then, other members of these signaling pathways have to be defined 
(e.g. RAF in the RAS/MEK/ERK pathway). A compound such as BAY 43-9006 has recently 
entered phase III clinical trial (Strumberg & Seeber, 2005) and could be used, whereas drugs 
targeting the PI3K/Akt pathway are in development. 
 
Outlook 
Genomic instability is a hallmark of cancer and leads to the expansion of a cell 
population resistant to apoptosis (Hanahan & Weinberg, 2000). Since disabling apoptosis by 
itself might favour genetic instability, it becomes plausible that both mechanisms could 
cooperate to increase the oncogenic and metastatic potential of transformed cells. During the 
initial stages of oncogenesis, an accumulation of random alterations in the unstable genome 
will be selected for growth advantage that affects a restricted set of oncogenes (for example, 
oncogenes that encode anti-apoptotic genes) and tumor-suppressor genes. 
Finally, genetic instability renders each tumor clonally heterogeneous and different 
from another one. In this study, cell lines showed different responses to various inhibitors. 
These results confirmed the interconnection between the signaling pathways and the 
singularity of each individual glioma cell line. In other words, each glioma cell line (or human 
primary tumor) needs to be specifically typed for its respective RTK expression pattern and 
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mutations in the EGFR, PDGFR and IGFR-I genes as of activities of downstream components 
(AKT and ERK). This genetic profiling of primary tumors would allow to provide an 
individualized (customized) therapy that may improve patient outcome.  
Another feature of GBM is a striking and dramatic induction of angiogenesis. VEGF 
signaling plays a crucial role in the process of neovascularisation. Interestingly, VEGF and its 
receptor are both expressed in glioblastomas (Heldin & Westermark, 1989; Plate & Risau, 
1995). Besides the proliferative and migratory effect mediated by EGFR and ErbB2, these 
tyrosine kinase receptors might also mediate the expression of pro-angiogenic molecules.  
Blocking EGFR and/or ErbB2 has been demonstrated to decrease pro-angiogenic molecules 
of tumor cells to inhibit tumor-associated angiogenesis. Then, inhibition of VEGF-induced 
angiogenic signals will target the essential role of angiogenesis in GBM development. 
AEE788 blocks EGFR and KDR, and also reduces secretion of VEGF via inhibition of 
EGFR. These combined effects render this compound highly attractive for the treatment of 
solid cancer such as GBM.  
Endothelial cells in the tumor vasculature are genetically more stable than tumor cells, 
and thus less likely to develop resistance. Anti-angiogenic therapy is directed specifically 
against endothelial cells in the newly-formed tumor microvasculature, so that the passage of 
drugs through the blood-brain-barrier (BBB) is not required and the therapy does not appear 
to induce acquired drug resistance. This approach allows escaping from the lack of effective 
methods of drug delivery, due to the presence of the BBB, which prevents the effective 
therapy of brain tumors. Then, the anti-angiogenic strategy (e. g. AEE788) to target both 
EGFR and KDR in combination with future inhibitors of AKT and ERK could be one 
potential therapy of glioblastoma. Impairing neovascularization of the tumor would result in 
starvation of the tumor. Since the potential anti-angiogenic ability of AEE788 cannot be 
tested in vitro, an orthotopic xenograft model is needed to address this question.  
 In vitro assays allow to determine easily and quickly the impact of a drug according to 
the genetic background. Considering that each cell line displays a specific combination of 
genetic defects, they represent the heterogeneous nature of gliomas, and the efficacy of the 
drug on a number of those could statistically mimic the potential effect of this drug on an in 
vivo model. Although xenograft studies are not fully predictive of the therapeutic efficacy of 
cancer therapies in clinical trials, orthotopic xenograft studies may offer additional 
information over cell culture studies. Thus, preliminary in vitro experiments are required for 
the determination of the spectrum of actions of given compounds on cell survival, on cell-
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cycle and on biomarkers. Development of such models enables to study simultaneously all the 
parameters previously described. 
 
 
Conclusion 
 
We found that GBM cells show resistance to treatment with drugs that target 
individual signaling pathways. As a single drug, AEE788 has provided new hope since its 
anti-migratory, cytostatic effect and anti-angiogenic properties have been shown in vitro and 
in vivo experiments. We have opened new approaches in the treatment of GBM, by 
combining AEE788 with the cytotoxic compound paputilone at doses of reduced toxicity, 
where synergistic effects were observed in 50% of the cell lines. Induction of apoptosis in 
these conditions was associated with downregulation of P-AKT and P-ERK. On the other 
hand, our results strongly suggest that such cells might successfully be brought to apoptosis 
by an additional treatment with compounds e.g. wortmannin or U0126 leading to the 
simultaneous downregulation of the PI3K/Akt and of the Ras/Raf/MEK/ERK signaling 
pathways. In the two strategies proposed, the readout of a successful therapy correlates with 
downregulation of proteins ERK and AKT. In the context of GBM treatment, we propose a 
combined therapy based on the simultaneous targeting of the Ras/Raf/MEK/ERK pathway 
with a protein kinase inhibitor and of the PI3K/Akt (PKB) signaling pathway with a 
phosphatidylinositol 3-kinase inhibitor. 
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Materials and methods 
 
Cell culture 
All cell lines were grown at 37°C in a 5% CO2 humidified atmosphere. Culture medium 
contained 10% fetal bovine serum (FBS, No S1810, Labforce, Basel, Switzerland) and 
Dulbecco’s Modified Eagle Medium (DMEM, No 10938-25, Invitrogen Corporation, UK) 
supplemented with glutamax  (No 35050-038, Invitrogen Corporation, UK) and antibiotics 
solution (No 15240-062, Invitrogen Corporation, UK). Cell detachment was performed with 1 
ml trypsin-EDTA 1X for 5 minutes at 37°C.  
 
Pharmacological inhibitors 
AEE788, patupilone, Gleevec and PKI-166 were provided by Novartis Pharma AG, Basel, 
Switzerland. They were prepared as a 10 mM stock solution dissolved in DMSO, aliquots 
were stored a –20°C. Wortmannin (Sigma) was prepared as a 1 mM stock solution in DMSO 
and stocked at 4°C. U0126 (Promega) as a 10 mM stock solution in DMSO, aliquoted and 
stocked at –20°C. TPA (LC laboratories) as a 2 mM stock solution in DMSO, aliquoted and 
stocked at –20°C. As remarks, TPA, U0126 and wortmannin were added every day during the 
experiment at their respective concentrations.  
 
Cell cycle profile and apoptosis 
Growing cells were treated during 24h, briefly washed with PBS and trypsinized. Cell 
suspension, was centrifuged at 800 rpm for 5 min, pelleted cells were fixed in ice cold 70% 
ethanol and kept at 4°C for 30 min. Cells were resuspended in a 1X PBS solution containing 
50 ng/ml propidium iodide (PI) and 50 µg/ml of RNAse. Percentages of cells were 
determined by flow cytometer (FACs) in G1 and G2/M for cell cycle and in sub-G1 for 
apoptosis, respectively.  
 
Proliferation 
BrdU incorporation analysis 
Cells were plated to grow during 24 hours in DMEM/10% FCS. Then, cells were incubated 
with AEE788 alone for 24h. BrdU was added to 10µM final concentration and cells incubated 
at 37°C during 1 hour prior harvesting cells, cells were prepared according to the 
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manufacturer’s instructions (Becton Dickinson, Franklin Lakes, NJ) and BrdU incorporation 
was analyzed by FACs analysis. 
 
Colony Forming Assay (CFA) 
Effect of the drug on cell proliferation was evaluated by measurement of the diameter of the 
resulting colony. 103 cells were plated in a 6 cm dish. After 24h, the drug was added and cells 
grown during 72h. Cells were washed twice with PBS, fixed during 10 min with MetOH/Ace. 
Acid (3:1)(v/v), and finally stained during 20 min with giemsa, washed several times with 
H2O. The colony counter takes the 3 parameters which defin the colony size (> 10, >50, >200 
µm). 
 
Migration 
Boyden chamber 
Migration assays were performed by precoating Boyden chamber well inserts with a 8.0 mm 
pore size (Becton Dickinson, Franklin Lakes, NJ) with 5 mg/ml collagen (Roche Diagnostics, 
Switzerland) for 2 h at room temperature and washed with PBS. Cells were pre-incubated in 
presence or absence of AEE788 (1 µM). After resuspension at a concentration of 1x106 
cells/ml in 10% FCS/DMEM, 100 µl were added to the upper chamber of the well insert, 
whereas 500 µl of DMEM 10% FCS containing also the appropriate conditions (EGF 100 
ng.ml-1, Sigma) is added to the lower chamber. Cells were allowed to migrate for 3 hours, 
after which time they were fixed in methanol and stained using Hematoxylin (Fluka). Cells 
remaining in the upper chamber were removed by wiping, and remaining cells adhering to the 
underside of the membrane were counted. Each condition was done in triplicate. 
 
Wound Healing Assay (WHA) 
Cells were plated in 6-well plates at 70% confluence in DMEM with 10% serum. At 24 h 
after seeding, the cell monolayers were wounded by scraping with a 200-µl plastic 
micropipette tip, washed, and then refed with complete DMEM. After 48 h, cells were fixed 
with 4% paraformaldehyde and photographed with an inverted microscope. 
 
Immunofluorescence microscopy  
Cells were fixed with 4% paraformaldehyde, permeabilized in phosphate-buffered saline 
(PBS) containing 0.5% Triton X-100, and blocked with FCS. Cells were incubated with anti-
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tubulin antibody for 1 h at room temperature, washed, and incubated with Cy3 (Molecular 
Probes, Eugene, OR). After final washes and mounting, nuclei were visualized by incubating 
the cells for 5 min in 0.1 mg/ml propidium iodide (Sigma, St. Louis, MO), cells were 
examined using a laser scanning deconvolution microscope with a 60X or 40X oil immersion 
objective. 
 
Nucleic acids analysis 
RNA isolation 
10 cm plates from each cell line were grown to a 90% confluence (2 per cell line). Medium 
was sucked off, and cells washed with 1x PBS, resuspended into 1,5 mL Trizol (Invitrogen 
Corporation, UK) and incubated for 3min at room temperature (RT), cell lysates were 
homogenized the cells and after 5 min the cells were transferred into 3 microfuge tubes and 
left at RT for another 3-5 min. 200 µl choloroform was added and tubes were vortexed for 30 
sec, and left at RT for 5 min. After centrifugation at 14000 rpm for 15 min at 4°C. To avoid 
genomic DNA and proteins contaminations, the upper (aqueous) phase was carefully 
transferred to fresh tubes. RNA was precipitated by addition of 500 µl isopropanol. RNA 
precipitate was pelleted down at 14000 rpm for 10 min at 4°C. Supernatant was removed and 
the RNA was washed with 1 mL ethanol and pelleted down at 12000 rpm for 5 min at 4°C, 
air-dried on ice and resuspended in 100 µl DEPC-treated H2O. 5 µl of RNA solution was 
added to 495 dH2O. Optical density was measured at 260 and 280 nm. The RNA in the 
remaining 95 µl was precipited by addition of 9,5 µl 4M LiCl, and 380 µl 100% EtOH.  
The concentration of RNA was calculated based on the OD260nm, 1 OD unit is equivalent to 40 
µg/mL 
 
cDNA synthesis 
The volume corresponding to 5µg of RNA was centrifuged at 14000 rpm and 4°C for 20 min. 
Supernatant was carefully withdrawn. Pellets were air-dried on ice and resuspended into 9 µl 
of DEPC-treated H20 + 1 µl of oligo dT (random hexamer). RNA samples were denatured at 
65°C for 5 min. cDNA synthesis master mix was added. 
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cDNA Synthesis Master Mix : 
5X buffer 4µ l 34.0 
(0.1M) DTT 1 8.5 
(10mM) dNTPs 2 17.0 
dH20 1 8.5 
RNAse out 1 8.5 
Thermoscript-RT 1 8.5 
 10µ l/tube 8.5 reactions 
10µl of cDNA Master Mix is made for each tube 
 
The cDNA synthesis took place at 50 °C for 1 hour. Thermoscript-RT was heat-inactivated at 
85 °C for 5 min and the RNA template was degraded by 1 µl RNAse H at 37 °C for 20 min. 
Finally, sample volume was adjusted to 50 µl by addition of DEPC-treated H20.  
 
PCR Master Mix 
dH20 18.5µ l 222.0µ l 
10x 2.5 30.0 
dNTPs 0.5 6.0 
Actin F 0.4 4.8 
Actin R 0.4 4.8 
Taq 0.2 2.4 
cDNA 2.5 --- 
 25 µ l/tube For 12 tubes 
 
Program used for amplification: 
 
 95°C   2 min 
 95°C  30 sec 
58 1 min  40 cycles 
72 1 min 
72  5 min 
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12.5µl of each sample was mixed with 2,5 µl of gel loading buffer (GLB) and run on a 1.0% 
agarose gel to check for amplification. 
 
EGFR Primer PCR Master Mix  
dH20 18.3µ l 73.2µ l 
10x 2.5 10.0 
dNTPs 0.5 2.0 
Primer sens 0.5 2.0 
Primer antisens 0.5 2.0 
Taq 0.2 0.8 
cDNA 2.5 - 
 25 µ l/tube 4 tubes 
 
The above samples were amplified in the thermo-cycler with following cycles: 
 
95°C   2 min 
94°C  30 sec 
60°C  1 min   35 cycles 
72°C  3 min 30 
72°C  5 min 
 
The PCR product (12,5 µl) was loaded on a 1% agarose gel. 
 
Primers (5’-3’) 
EGFRs: gcg atg cga ccc tcc gga cg      (initiation codon) 
EGFRas: ggt cat gct cca ata aat tc   (stop codon) 
 
Protein analysis 
Protein extraction 
Cell were washed with PBS, scraped and resuspended into 1X SDS Sample Buffer (62,5 mM 
Tris/Hcl, 2% SDS, 10% Glycerol, 50 mM DTT). Cell lysates were boiled at 95°C during 5 
minutes and aliquots were made and stored at –20°C. 
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Western analysis 
Protein were separated by size on a SDS-PAGE gel (8 to 14%), and transferred on a 
nitrocellulose membrane (Hybond-C, Amersham Life Sience) for 3 hours at 0.8 A at 4°C. 
Membrane was blocked with 5% non fat dry milk in TBS-Tween (10 mM Tris, 150 mM 
NaCl, 0,05% Tween 20) and 1% BSA. Primary antibodies were diluted (next section) either 
in TBS-Tween or in 5% non fat dry milk, 1% BSA in TBS-Tween overnight at 4°C. Three 
additional washes with TBS-Tween were performed before incubation with the appropriate 
secondary antibody. Then, after three washes in TBS-Tween, signal detection by 
chemiluminescence (ECL detection kit, Amersham) was performed.  
 
List of antibodies 
 
 
 
M: mouse, R: rabbit, G: Goat, U: Upstate Biotechnology, Lake NY, SC: Santa Cruz, S: 
Sigma, St. Louis, MO, C: Cell Signaling, JIR: Jackson Immunoresearch Laboratories , P: 
Pierce 
 
* gift from Bryan Hemmings (FMI).
Name Host 1st dilution 2nd dilution Reference Company
4G10 M 2000 20000 05-321 U
ACTIN R 2000 20000 A5060 S
AKT R 500 5000 *
P-AKT M 5000 10000 05-669 U
ERK2 R 1000 10000 sc-154 SC
P-ERK M 500 10000 sc-7383 SC
EGFR G 100 10000 sc-03 SC
EGFR-PY 992 R 500 5000 9922 C
EGFR-PY 1173 G 100 5000 sc-12351 SC
ErbB2 R 500 20000 06-562 U
ErbB2-PY 877 R 250 5000 9922 C
ErbB2-PY 1248 R 250 5000 9922 C
ErbB3 R 100 10000 sc-285 SC
ErbB4 R 100 10000 sc-283 SC
PTEN R 1000 10000 07-016 U
KDR M 200 10000 07-158 U
PARP R 1000 10000 9542 C
p21 M 1000 5000 sc-6246 SC
anti-mouse 31432 P
anti-rabbit 31462 P
anti-goat 31402 P
CONFOCAL
Tubulin M 100 sc-6251 SC
Cy3 anti-M 500 715-165-150 JIR
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Abbreviations 
 
AC50 (nM): concentration where 50% of apoptosis is reached 
 CDK4: cyclin-dependent kinase 4 
CML: chronic myeloid leukemia 
CNS: central nervous system 
DNA PK: DNA dependent ptotein kinase 
EC50: 50% effective concentration 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor  
ERK1/2: extracellular regulated-signal kinase 1 and 2 
GBM: glioblastoma multiforme 
GIST: gastrointestinal stromal tumor 
GSK3!: glycogen s!nthase kinase-3! 
HDM2: human double minute 2 
IGFR-I: insulin-like growth factor receptor-1 
MAPK: mitogen activated protein kinase 
MEK: mitogen-activated kinase/ERK kinase  
MEKK1: mitogen-activated protein kinase kinase 1 
MNK: p38 MAPK –dependent kinase  
NSCLC: non small cell lung cancer  
NF1: neurofibromin 
NF-"B: nuclear factor of "B  
PDGF: platelet-derived growth factor 
PDGFR: platelet-derived growth factor receptor 
PDK1: 3-phosphoinoside-dependent protein kinase 
PI3K: phosphatidylinositol 3-kinase  
PLA2 :phospholipase A2 
PKI: protein kinase inhibitor 
PTEN: phospatase tensin homolog 
RB: retinoblastoma susceptibility protein  
RSK: p90 ribosomal protein S6 kinase  
RTK: receptor tyrosine kinase 
RTKi: receptor tyrosine kinase inhibitor 
SCF: stem cell factor 
VEGF: vascular endothelial growth factor 
VEGFR: vascular endothelial growth factor receptor 
WHO: world health organization 
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Annex I: Mouse models of glioma and their construction. Signal transduction pathways are 
activated by expression of the indicated genes. Cell cycle arrest pathways are experimentally 
disrupted by the indicated genetic alterations. GFAP: Glial Fibrillary Acidic Protein, NSC: 
Neural Stem Cells. 
 
 
 
 
     
Signal transduction            Cell cycle arrest         Cell of origin                          Reference
    abnormalities                          disruption
Kras and Akt                                             
Nestin 
expressing            
progenitor                                              
Holland et al., 2000                                      
Ras 
GFAP
expressing            
astrocyte                                             
MDM2,CDK4 overxexpression
 p53  deletion                                           
Ding et al., 2002                                           
Nestin 
expressing            
progenitor                                              
NSC and
Astrocyte                                             
EGFR  Ink4a/Arf-/-   
        
 Ink4a/Arf-/-   
Ink4a/Arf+/-         
EGFR 
NF1 deletion p53 deletion  
        
Reilly et al., 2000                                         
Rich et al., 2001                                           
Kras and Akt                                             Ink4a/Arf-/-   
        
Astrocytoma                                          
GFAP expressing astrocyte
and                                             
Nestin expressing progenitor                                              
                                          
Hras p53, RB deletion and 
telomere maintenance  
        
Astrocyte                                             
Holland et al., 1998                                     
Bachoo et al., 2002                                  
Uhrbom et al., 2002                                 
Uhrbom et al., 2005                                           
GFAP expressing astrocyte
Nestin expressing progenitor                                              
Kras and Akt                                       Arf -/-                                      
Kras and Akt                             Ink4a -/- OR  Arf-/-  
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Annex II: Expression of ErbB receptors and their ligands in cancer. (TGF-#, transforming 
growth factor-#; NRG1, neuregulin-1; HB-EGF, heparin-binding epidermal growth factor). 
 
 
 
 
Molecule Nature Type of Notes
dysregulation  cancer
Ligands
TGF-! Overexpression Prostate Expressed by stroma in early, androgen-dependent 
prostate cancer and by tumours in advanced,
androgen-independent cancer
Overexpression Pancreatic Correlates with tumour size and decreased patient
survival; may be due to overexpression of Ki-Ras, 
which also drives expression of HB-EGF and NRG1
Overexpression Lung, ovary, Correlates with poor prognosis when co-expressed 
colon with ErbB1
NRG1 Overexpression Mammary Necessary, but not sufficient for tumorigenesis 
adeno-carcinomas  in animal models
Receptors
ErbB1 Overexpression Head and Significant indicator for recurrence in operable 
neck, breast, bladder breast tumours; associated with shorter disease-
prostate, free and overall survival in advanced breast 
kidney, NSCLC cancer;may serve as a prognostic marker for 
bladder, prostate, and non-small-cell lung cancers
Overexpression Glioma Amplification occurs in 40% of gliomas; 
overexpression correlates with higher grade and
reduced survival
Mutation Glioma, lung, Deletion of part of the extracellular domain yields  
ovary, breast a constitutively active receptor
ErbB2 Overexpression Breast, lung  Overexpressed owing to gene amplification in
pancreas, 15–30% of invasive invasive ductal breast cancers
colon Overexpression correlates with tumour size, spread
oesophagus, of the tumour to lymph nodes, high grade,
endometrium, high percentage of S-phase cells, aneuploidy and
cervix lack of steroid hormone receptors
ErbB3 Expression Breast, colon Co-expression of ErbB2 with ErbB1 or ErbB3  
gastric, breast cancer improves predicting power 
and other carcinomas
Overexpression Oral squamous Overexpression correlates with lymph node
cell cancer involvement and patient survival
ErbB4 Reduced Breast, prostate Correlates with a differentiated phenotype
expression
Expression Childhood Co-expression with ErbB2 has a prognostic value
medulloblastoma
Adapted from Yarden Y. & Sliwkowski M. X. Nat. Rev. Mol. Cell Biol. 2: 127-37 (2001)
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 Annex III: Some examples of drugs targeting EGFR/ErbB2 
 
 
 
    
 
 
 
 
 
 
 
  
Adapted from Holbro et al., 2003 
Pfizer
GlaxoSmith Kine
Wyeth
Novartis
Novartis
    Roche/Genentech/OSI
AstraZeneca
Abgenix
YM Biosciences
Merck
Imclone Systems
Hum. mAb
Hum. mAb
Hum. mAb
Chim. mAb
TKI
TKI
TKI
TKI
TKI
TKI
TKI EGFR/ErbB2 Phase I
EGFR Phase I
EGFR/ErbB2 Phase I
EGFR/ErbB2 Phase II
EGFR/ErbB2 Phase I
EGFR Phase III
EGFR Phase II
            EGFR Phase I
EGFR Phase I/II
            EGFR Phase I/II
            EGFR Phase III
       Target             Status      Company         Type     Compound
    AEE788
    EKB-569
    GW2016 
 
    CI-1033
  
    PKI-166
    Tarceva (OSI-774)
 Iressa (ZD1839, Gefinitib)
    ABX-EGF
    Thera CIM
     EMD 72000
     Cetuximab (C225)
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Annex IV:  
a. List of glioma cell lines and their respective genetic status for PTEN-p53-p16/p14 
 
 
Name:   PTEN   p53    p16/14 
 
LN-71   mut   mut   del 
LN-215  mut   mut   wt 
LN-229  wt   mut   del 
LN-401  mut   mut   del 
LN-405  mut   mut   wt 
U87MG  wt   wt   del 
SF767   wt   wt   wt 
U343MG  mut   wt   del 
BS-125.3.2  mut   del   +/- 
BS-125II.2  mut   del   +/- 
 
TP53, PTEN, p16 status in glioma cell lines. mut: mutated, del: homozygous deletion, wt: wild-type, +/-: one allele deleted. 
(Ishii et al., 1999)  
 
 
b. Other cell lines tested 
 
Name:   PTEN   p53    p16/p14 
 
 
U373   mut    mut   wt 
Hs683   wt   mut   del 
 
 
 
Combination of sublethal concentrations of epidermal
growth factor receptor inhibitor and microtubule
stabilizer induces apoptosis of glioblastoma cells
Mike Failly, Serdar Korur, Viviane Egler,
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Abstract
The oncogenic epidermal growth factor receptor (EGFR)
pathway triggers downstream phosphatidylinositol 3-
kinase (PI3K)/RAS-mediated signaling cascades. In trans-
genic mice, glioblastoma cannot develop on single but only
on simultaneous activation of the EGFR signaling media-
tors RAS and AKT. However, complete blockade of EGFR
activation does not result in apoptosis in human glioblas-
toma cells, suggesting additional cross-talk between
downstream pathways. Based on these observations, we
investigated combination therapies using protein kinase
inhibitors against EGFR, platelet-derived growth factor
receptor, and mammalian target of rapamycin, assessing
glioblastoma cell survival. Clinically relevant doses of
AEE788, Gleevec (imatinib), and RAD001 (everolimus),
alone or in combinations, did not induce glioblastoma cell
apoptosis. In contrast, simultaneous inactivation of the
EGFR downstream targets mitogen-activated protein/
extracellular signal-regulated kinase (ERK) kinase and
PI3K by U0126 and wortmannin triggered rapid tumor
cell death. Blocking EGFR with AEE788 in combination
with sublethal concentrations of the microtubule stabilizer
patupilone also induced apoptosis and reduced cell
proliferation in glioblastoma cells, accompanied by re-
duced AKT and ERK activity. These data underline the
critical role of the PI3K/AKT and the RAS/RAF/mitogen-
activated protein/ERK kinase/ERK signaling cascades in
the cell-intrinsic survival program of sensitive glioblastoma
cell lines. We conclude that drug combinations, which
down-regulate both ERK and protein kinase B/AKT
activity, may prove effective in overcoming cell resistance
in a subgroup of glioblastoma. [Mol Cancer Ther 2007;
6(2):773–81]
Introduction
Glioblastoma multiforme is the most frequent malignant
neoplasm of the human central nervous system. Surgery
can only control the highly proliferative component of the
disease, whereas widespread tumor cell infiltration into
normal brain areas resists radiotherapy and chemotherapy
(1, 2). Amplification and overexpression of the gene
encoding the epidermal growth factor (EGF) receptor
(EGFR) are detected in f50% of glioblastomas and are
mainly associated with disease progression (3, 4). EGFR is a
member of the ErbB family of receptor tyrosine kinases (5).
Small molecular weight compounds with EGFR protein
kinase inhibitory (PKI) activity, such as PKI-166 or AEE788,
have a cytostatic effect in vitro on tumor cells that
overexpress EGFR (6, 7). In addition, treatment of non–
small cell lung cancer with the EGFR PKI imatinib
(gefitinib) resulted in tumor growth control in 10% of
patients (8). In fact, tumors that responded to gefitinib
specifically carried specific mutations in the EGFR tyrosine
kinase domain (8–10). Although responses to gefitinib have
also been observed in a limited number of glioblastoma
cases (11), a specific molecular profile is associated with
response that differs from the lung signature (12–15). To
date, several small molecular weight inhibitors, such as
Gleevec or erlotinib/gefinitib, applied as monotherapies
for the treatment of gliomas, only resulted in limited
effectiveness (16). This has supported the hypothesis that
combination of drugs would be a more appropriate
treatment for glioma.
EGF mediates signaling via phosphatidylinositol 3-kinase
(PI3K)/AKT and RAS/mitogen-activated protein/extracel-
lular signal-regulated kinase (ERK) kinase (MEK)/ERK
pathways (17–19), which are redundantly stimulated by
other activated growth factor receptors (e.g., the insulin-
like growth factor receptor-I; ref. 20). In at least 50% of
glioblastoma, PI3K is activated either by loss of function
of the tumor suppressor PTEN (21) or by gain-of-function
mutations in the PIK3CA gene, which encodes the p110
catalytic subunit of PI3K (22). Interestingly, activated
protein kinase B (PKB)/AKT cooperated with RAS in the
induction of malignant gliomas in a murine brain tumor
model (23). Furthermore, activation of PKB/AKT has been
detected in several types of human cancers and found to
be associated with poor clinical outcome (24–26) and
resistance to chemotherapy and radiotherapy (24, 27, 28).
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Although no RAS mutations have been detected in
glioblastoma, high levels of RAS-GTP have been docu-
mented in high-grade astrocytomas (29, 30). It has been
suggested that ERK plays a critical role in cellular
transformation and resistance to apoptosis (31). Evidence
for a cooperation between AKT and RAS has been proven
by a transgenic mouse model in which both oncogenes are
ectopically expressed in normal astrocytes, giving rise to
glioblastoma, whereas neither AKT nor RAS alone was
sufficient for tumor induction (23).
Several examples of combined therapies have recently
undergone advanced clinical trials in cancer treatment. For
example, lapatinib with tamoxifen has been tested together
in breast cancer (32), and in xenografted tumors (32), PKI
AEE788 has been associated with the rapamycin-derivative
RAD001 for the treatment of glioblastoma (33–35).
Successful drug combinations allow the use of lower
doses, possibly reducing toxicity and limiting the degree
of acquired drug resistance. Given the limited efficacy of
PKI to induce cell death in rapidly proliferating tumor cells,
these inhibitory drugs may depend on the coadministration
of a cytotoxic drug for the induction of cell death rather than
on the coadministration of a second cytostatic compound.
The principle of cytotoxicity of patupilone (epothilone B,
EPO906) relies on the inhibition of microtubule depolymer-
ization, which is lethal for all dividing cells. The antitumor
activity of patupilone has been proven in vitro and in vivo in
lung, breast, colon, and prostate cancers (36). Patupilone
also shows clinical activity in a range of solid tumors (37)
and is now in phase III clinical development.
In the present study, we examined the induction of cell
death on glioblastoma lines in vitro by targeting EGFR/
ErbB2 by the receptor tyrosine kinase inhibitor AEE788
alone or in combination with the cytotoxic compound
patupilone. We further evaluated the activation status of
the EGFR downstream signaling mediators PKB/AKT and
ERK following combined treatment with patupilone
and AEE788. Our study points to a critical role of both
PI3K and ERK in glioblastoma cell survival.
Materials andMethods
Cell Culture
All cell lines were grown at 37jC in a 5% CO2 humidified
atmosphere. DMEM culture medium was supplemented
with 10% FCS and standard antibiotics. Cells were
detached with 1 mL trypsin-EDTA (1) for 5 min at
37jC. The genetic status of all cell lines at p53, p16, p14ARF ,
and PTEN tumor suppressor genes has been previously
reported (38, 39).
Pharmacologic Inhibitors
AEE788, RAD001, and patupilone (provided by Novartis
Pharma AG, Basel, Switzerland) and U0126 (Promega,
Madison, WI) were dissolved in DMSO as 10 mmol/L
stocks and stored as aliquots at 20jC. Wortmannin
(Sigma, St. Louis, MO) was prepared as a 1 mmol/L stock
solution in DMSO and stored at 4jC, and 12-O-tetradeca-
noylphorbol-13-acetate (TPA; LC Laboratories, Woburn,
MA) was prepared as a 2 mmol/L stock solution in DMSO,
aliquoted, and stored at 20jC. Treatment of the cells with
TPA, U0126, or wortmannin consisted of daily additions
without replacing the medium.
Measurement of Cell Proliferation and Cell Cycle
Profile
In experiments shown in Fig. 1B, cells were grown for
24 h in DMEM supplemented with 10% FCS and for an
additional 24 h in the presence of the drug. Bromodeoxyur-
idine (BrdUrd) was added 1 h before cell harvesting to a
10 Amol/L final concentration. Fluorescence-activated cell
sorting analysis was done according to the manufacturer’s
instructions (Becton Dickinson, Franklin Lakes, NJ). The cell
proliferation assays presented in Figs. 2C and 3B were
done with the Biotrak ELISA System version 2 (Amersham
Biosciences Corp., Piscataway, NJ) according to the manu-
facturer’s instructions. Cells (5  103) were seeded in
96-well plates and grown for 24 h, and drugs were applied
for an additional 24 h. BrdUrd incorporation was allowed
during the last 2 h of treatment. In experiments shown in
Fig. 1D, cells were grown for 24 h in DMEM supplemented
with 10% FCS and for an additional 24 h in the presence of
the drug. Cell DNA content and apoptosis were analyzed on
a FACSCalibur. Cells were trypsinized and fixed in 70% ice-
cold ethanol for 1 h and stained with 50 Ag/mL propidium
iodide for fluorescence-activated cell sorting analysis. The
percentages of cells in the cell cycle phases are reported
(results from three independent experiments).
Measurement of Apoptosis
Expanding cells were subjected to drug treatment for
24 h, briefly washed with PBS, and trypsinized. Cell
suspension was pelleted at 800 rpm for 5 min, fixed in
ice-cold 70% ethanol, and kept at 4jC for 30 min. Cells were
resuspended in a 1 PBS solution containing 50 ng/mL
propidium iodide and 50 Ag/mL RNase. Percentage of cells
in sub-G1 for apoptosis was determined by flow cytometry.
Protein Extraction andWestern Blot Analysis
Cells were washed with PBS, resuspended in 1 SDS
sample buffer (62.5mmol/LTris-HCl, 2%SDS, 10%glycerol,
50 mmol/L DTT), and boiled at 95jC during 5 min; aliquots
were stored at 20jC. Proteins (30 Ag) were separated by
size on SDS-PAGE gels (10%) and transferred to nitrocellu-
lose membranes (Hybond ECL, Amersham Biosciences).
Western blot analysis was done using antibodies against the
following proteins: phosphorylated AKT (Upstate Biotech-
nology, Lake Placid, NY), ERK1/2, phosphorylated ERK,
phosphorylated EGFR (Tyr1173), and EGFR (Santa Cruz
Biotechnology, Santa Cruz, CA) and actin (Sigma). The anti-
AKT antibody was a gift from Dr. Brian Hemmings
(Friedrich Miescher Institute, Basel, Switzerland). Western
blots were developed with enhanced chemiluminescence
reagents (Pierce, Rockford, IL).
Results
SpecificTargeting of the EGF Signaling Pathway by
AEE788
Nearly 50% of primary glioblastomas exhibit amplifica-
tion of the EGFR gene (3, 4), which is also associated with
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poor prognosis. For this reason, the inhibitor of EGFR and
of ErbB receptor protein kinase activities AEE788 has been
considered to be a potent drug to induce cell death in
glioblastoma cell lines. AEE788 was tested for its ability to
induce cell growth arrest and apoptosis in various cell lines
derived from glioblastoma, for which the genetic status of
established cancer genes had been previously defined
(Fig. 1A; refs. 38, 39). For a preliminary determination of
the minimal drug concentration needed to fully prevent
EGFR activation by EGF, increasing concentrations of
AEE788 were applied to the LN229 glioblastoma cell line,
and EGFR/ErbB receptor activation status was monitored
by the presence of EGFR phosphorylated at Tyr1173. To
completely block receptor phosphorylation, 1 Amol/L was
needed (data not shown). Further time course experiment
done with 1 Amol/L AEE788 showed a strong inhibition of
the transient phosphorylation of Tyr1173 as well as of the
degradation of the receptor protein in all seven glioblasto-
ma cell lines tested (Fig. 1B).
Increasing concentrations of AEE788 were applied to
the glioblastoma cell lines, and proliferation was assayed
by integration of BrdUrd after 1 day. At a 1 Amol/L
concentration, AEE788 gives up to 20% of proliferation
reduction compared with the control cell population
(Fig. 1C). Cell cycle analysis after 24 h of 1 and 10 Amol/L
of AEE788 treatment shows an increase of cell population in
the G1 phase (Fig. 1D).
Cell viability was assayed by flow cytometry after 24, 48,
and 96 h. Very low or no apoptosis was induced at drug
concentrations <2 Amol/L as late as 96 h (Fig. 2A). High
levels of apoptosis were observed at unphysiologically
high concentration (10 Amol/L) in five of the seven cell
lines (SF767, LN215, U373, LN229, and LN71). Under the
same condition, LN401 and Hs683 did not show significant
levels of apoptosis. Because AEE788 was not capable of
inducing strong apoptosis in glioblastoma cells when used
as a single drug, we tested whether a specific double or a
triple combination of compounds would significantly
increase the induction rate of apoptosis. For this purpose,
we combined suboptimal doses of AEE788 (0.5 Amol/L)
with two additional biological drugs: Gleevec (imatinib,
0.5 Amol/L) and RAD001 (everolimus, 20 nmol/L). In
gliomas, Gleevec is being explored as a PKI of platelet-
derived growth factor receptor (34), which is activated in
Figure 1. Treatment of glioblasto-
ma cell lines with EGFR inhibitor. A,
genotyping of used glioma cell lines
by Ishii et al. (39). B, cells were
preincubated in the presence or
absence of 1 Amol/L of the EGFR
inhibitor AEE788 during 30 min and
stimulated with 100 ng/mL EGF for
10, 60, and 300 min. EGFR, phos-
phorylated EGFR (Tyr1173), and actin
were detected by Western blot anal-
ysis of cell lysates. C, cells were
incubated during 4 d with increasing
concentrations of AEE788 (0, 1, 2,
5, and 10 Amol/L). Proliferation was
measured by BrdUrd and flow cytom-
etry. Experiments were done in trip-
licate. Points, average of three
independent determinations; bars,
SD. D, cell cycle phase analysis on
glioblastoma cell lines on 1 and 10
Amol/L of AEE788 treatment.
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primary tumors (40, 41). Platelet-derived growth factor
receptor phosphorylation levels correlated with sensitivity
to Gleevec in glioma primary cultures (42). RAD001, a
derivative of rapamycin, inhibits mammalian target of
rapamycin, leading to inactivation of ribosomal S6K1 and
inhibition of cap-dependent translation (43).
The application of the combined drugs to 10 glioblastoma
cell lines for 4 days revealed that there was a combination-
specific and a cell line–specific response with regard to
induction of cell death (Fig. 2B). The cell lines could be
divided into three categories. One group (SF767, LN18, and
LN215; Fig. 2B, left) showed a modest additive induction
of apoptosis by all of the three drugs, reaching a maximum
of 35% of cell death with the triple combination. A second
group of glioblastoma cell lines (LN401, LN71, LN229, and
LN319; Fig. 2B, middle) was basically insensitive to all drug
combinations, showing the same rate of apoptosis as
untreated cells. The third group (Hs683, U373, and U343;
Fig. 2B, right) exhibited a relatively high level of basal
apoptosis (15–20%), which was, however, decreased by the
three drugs applied together. Especially, RAD001 exhibited
an antiapoptotic effect, alone or in combination. No differ-
ences in apoptosis rate were evidenced between PTEN-
mutant (LN215, LN401, LN71, and U373) and wild-type
(Hs683, SF767, and LN229) cell lines on RAD001 applica-
tion. Although, in theory, RAD001 was expected to
overcome the constitutive AKT activation resulting from
loss of PTEN activity.
Taken together, the results indicated that neither single
nor combined application of the three biological drugs, at
physiologic concentration, was able to strongly induce cell
death in glioblastoma cell lines.
Induction of Apoptosis in Glioblastoma Cell Lines by
Patupilone
Because neither the single nor the combined application
of the three biological drugs led to a consistent induction of
apoptosis, we tested whether the combination of AEE788
with a cytotoxic drug could result in a more cooperative
induction of apoptosis. Patupilone is a member of the
group of epothilones, which represent a new class of low
molecular weight compounds that target microtubules by
inhibiting their depolymerization and therefore impairs cell
division (44). Patupilone prevents chromosome alignment
at metaphase and drives cells to undergo apoptosis (45). It
has been shown to exhibit antitumor activity in vitro and
in vivo (36, 37). As a result of inhibition of microtubule
depolymerization, after addition of patupilone, dramatic
changes in cell morphology occurred within 18 h (Fig. 3A,
right). To investigate its ability to induce apoptosis,
glioblastoma cells were treated with increasing concen-
trations of patupilone in the picomolar and nanomolar
concentration range for 4 days (Fig. 3A, left). Although
100% apoptosis was induced in all cell lines when the
highest drug concentration (35 nmol/L) was applied, levels
of apoptosis induced by 0.7 nmol/L patupilone strongly
varied between the cell lines, from Hs683 and LN401, the
most resistant, to LN229, the most sensitive one.
Combined Treatment with AEE788 and Patupilone
Strongly Induced Apoptosis and Reduced Proliferation
of Glioblastoma Cells
AEE788 (1 Amol/L) was applied together with increasing
concentrations of patupilone on cell lines LN71, LN229,
Hs683, and SF767, and cell survival was determined after
4 days (Fig. 3B). The combined drugs induced apoptosis in
Figure 2. Survival of glioblastoma
cell lines on treatment with EGFR
inhibitor and in combination with
Gleevec and RAD001. A, cells were
incubated during 4 d with increasing
concentrations of AEE788 (0, 1, 2,
5, and 10 Amol/L). Apoptosis was
measured by flow cytometry. Experi-
ments were done in triplicate. Col-
umns, average of three independent
determinations; bars, SD. B, combi-
natorial study of biological drugs
AEE788 (A), Gleevec (G), and
RAD001 (R) on glioma cell survival.
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a cooperative manner in LN71 and SF767 but not in Hs683
and LN229 cell lines. In LN71 and SF767 lines, the
patupilone concentration required to induce apoptosis in
50% of cells (AC50) revealed that AEE788 acted as a
sensitizer, reducing the patupilone concentration from a
nanomolar to a picomolar concentration range. Thus,
addition of AEE788 shifted down the amount of patupilone
required to induce apoptosis in 50% of cells, up to 2 orders
of magnitude in SF767 cells. It is noteworthy that the
synergistic effect of patupilone on those glioma cell lines
seemed independent of their respective sensitivities to
AEE788. Consistent with the absence of synergy of
both compounds on LN229 cells, also proliferation was
not affected either by AEE788 or patupilone or by the
combination of both drugs. In contrast, SF767 cells, on
which the AEE788/patupilone synergized the best, had a
significant reduction of proliferation up to 80% (P < 0.001)
after each individual or combined drug application
(Fig. 3C).
Simultaneous Inhibition of Both ERK1/2 and AKT
KinaseActivities Parallels the Induction of Apoptosis
Both signaling pathways, PI3K/AKT and RAS/MEK/
ERK, are under the control of EGF-directed activation of
ErbB receptors. To investigate the activation of these two
pathways, phosphorylation status of the kinases AKT and
ERK was chosen as readouts. AEE788 (1 Amol/L) and
patupilone (0.7 nmol/L), alone and in combination, were
applied for 24 and 72 h to the four glioblastoma cell lines
that differed remarkably in their sensitivities toward those
drugs. In contrast to LN229 and Hs683, LN71 and SF767
Figure 3. Combined treatment of
glioblastoma cells stabilizing micro-
tubules and blocking EGFR. A, in-
creasing concentrations of patupilone
(0.05, 0.1, 0.7, 5, and 35 nmol/L)
were applied to seven cell lines for
4 d and the percentage of viable cells
was determined using flow cytome-
try. Points, average of three indepen-
dent determinations; bars, SD.
Confocal microscopy of LN229 cells
after 18 h of patupilone treatment. B,
cells were treated for 4 d either with
increasing concentrations of patupi-
lone alone or in combination with
1 Amol/L AEE788. Cell survival was
measured by flow cytometry. Points,
average of three independent experi-
ments; bars, SD. C, cells were
treated with 1 Amol/L AEE788 and/
or 0.7 nmol/L patupilone and assayed
for proliferation with BrdUrd by
ELISA. D, top, cells were incubated
during 24 h and 3 d with patupilone
(0.7 nmol/L), AEE788 (1 Amol/L), or
both. Western blot analysis was done
on cell lysates. NT, no treatment;
A, AEE788; P, patupilone. Bottom,
poly(ADP-ribose) polymerase (PARP )
cleavage after 24 h.
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showed full down-regulation of phosphorylation of
both protein kinases after 3 days of combined treatment
(Fig. 3D), accompanied by widespread apoptosis between
85% and 95% of cells. In contrast, LN229 and Hs683 still
retained strong phosphorylation of the two protein kinases
and showed much lower levels of apoptosis. These results
suggested a link between the simultaneous inhibition of the
two EGF-dependent signaling pathways and the induction
of apoptosis triggered by the combination of patupilone
and AEE788. To support this hypothesis, we analyzed the
cleavage status of poly(ADP-ribose) polymerase, which
triggers caspase-dependent apoptosis (46, 47). The cleaved
form of poly(ADP-ribose) polymerase was indeed detected
in glioblastoma cells undergoing apoptosis (Fig. 3E).
Simultaneous Inhibition of AKTand MEK Coopera-
tively Induces Apoptosis in a Subgroup ofGlioblastoma
Cell Lines
To test whether sensitivity of LN71 and SF767 cells to
the AAE788-patupilone combination is due to low phos-
phorylation levels of AKT and/or ERK, inhibitors of PI3K
(wortmannin) and MEK (U0126) were used to abrogate
activation of AKT and ERK pathways. The potential to
induce cell death was tested by applying single or
combined inhibitors to four glioblastoma cell lines and
measuring the proportion of apoptotic cells (Fig. 4A). When
used as a single compound, U0126 was able to induce a
significant level of apoptosis in LN215 and LN229 cells but
to a much lesser extent in U373 and LN401 cells, whereas
wortmannin alone had no or very little effect. However,
strong induction of apoptosis was caused by the combina-
tion of the two inhibitors. On U0126 application, prolifer-
ation was significantly decreased up to 50% in LN229
cell line (P < 0.001), whereas U373 cells showed a 20%
reduction. Again, wortmannin alone had no effect on
reduction of proliferation on both LN229 and U373 cells,
and no synergistic effect was present after drug combina-
tion (Fig. 4B).
U373 and LN401 generally exhibited much less sensitiv-
ity toward the two inhibitors. To examine the long-term
effect of the inhibitors on phosphorylation of AKT and
ERK, the two most sensitive and the two much less
sensitive cell lines were treated for 24 h as well as for
3 days by applying fresh doses of the compounds daily.
The activation status of AKT and ERK was determined
as a readout for drug efficiency (Fig. 4C). In response to
the combination of U0126 and wortmannin, a decrease of
Figure 4. Combined treatment of
glioblastoma cells blocking PI3K and
MEK. A, cell lines were treated with
the MEK inhibitor U0126 (20 Amol/L)
and/or the PI3K inhibitor wortmannin
(1 Amol/L) for 3 d, whereby the
addition of both drugs was repeated
every day. Percentage of apoptotic
cells was measured using flow
cytometry. Columns, mean of three
independent experiments; bars, SD.
B, cells were treated with 20 Amol/L
U0126 and/or 1 Amol/L wortmannin
and assayed for proliferation with
BrdUrd by ELISA. C, Western blot
analysis was done to determine the
relative phosphorylation levels of
ERK1/2 and AKT after 3 d of treat-
ment. U, U0126; W, wortmannin.
D, poly(ADP-ribose) polymerase
(PARP) cleavage after 24 h.
Synergistic Induction of Glioblastoma Cell Apoptosis778
Mol Cancer Ther 2007;6(2). February 2007
phosphorylated ERK and phosphorylated AKT occurring
in all glioblastoma lines confirmed the activity of the
two drugs used. Unexpectedly, on treatment with the
MEK inhibitor, U0126, U373, and LN229 cell lines show
a decrease of phosphorylated AKT levels, suggesting a
cross-talk between the RAS/MEK/ERK and PI3K/AKT
pathways.
In the sensitive cell lines LN215 and LN229, simultaneous
inactivation of protein kinases AKT and MEK was
associated with poly(ADP-ribose) polymerase cleavage
and apoptosis (Fig. 4D). However, in the resistant cell lines
U373 and LN401, AKT and MEK inactivation was not
sufficient to trigger apoptosis. There was no correlation
between glioblastoma cell line sensitivity or resistance to
apoptosis and a given genotype (Fig. 1A).
Phorbol Ester TPA Restores Activation of MEK and
Inhibits Induction of Apoptosis
Phorbol ester TPA activates protein kinase C and ERK1/2,
thereby modifying mitogenic signaling pathways (44, 48,
49). When exposed to 20 or 100 nmol/L of TPA, LN215
and LN229 cells showed a strong increase of phosphorylated
ERK levels (Fig. 5A). Treatment of the cell lines with
combined U0126 and wortmannin for 4 days in the presence
of TPA (20 or 100 nmol/L) led to a substantial increase of
activated ERK1/2, whereas phosphorylation was complete-
ly down-regulated without TPA (Fig. 5A). In parallel, the
extent of the induction of apoptosis was determined after
4 days under the same conditions, revealing that the
addition of TPA to both glioblastoma cell lines substantially
decreased the induction of apoptosis caused by the two
inhibitors (Fig. 5B). Taken together, the results further
supported the model of a correlation between down-
regulation of the two signaling pathways and induction of
apoptosis.
Discussion
We report that the combination of the inhibitor of EGFR
kinase AEE788 and of the microtubule depolymerization
inhibitor patupilone synergistically induced death of
glioblastoma cells. Of high interest is that this synergy
occurred at drug concentrations that were not effective to
induce cell death when each drug was applied alone.
AEE788 alone at 1 Amol/L only induced low levels of
apoptosis in glioblastoma cells in vitro . Its main antitumor
activity consists of inhibition of cell growth and motility
(50). Consistently, survival of animals bearing intracranial
tumors had been extended by giving AEE788 at concen-
tration below the maximally tolerated dose (34) and
confirmed a role of AEE788 as an antitumor agent.
However, lasting responses cannot be obtained with a
cytostatic effect but require induction of tumor cell death,
which may only be achieved by drug combinations.
Therefore, we designed a strategy to trigger glioblastoma
cell apoptosis by combining the PKI AEE788 with
patupilone, a compound with strong cytotoxic potential
against various cancer types and also against multidrug
resistance cancer cell lines (51). Glioblastoma cell death
could be triggered in all tumor cell lines in vitro by
35 nmol/L patupilone, a dose that can already be toxic
in vivo . Interestingly, synergistic induction of apoptosis was
observed in glioblastoma cells when using 1 Amol/L
AEE788 in combination with only 0.1 nmol/L patupilone.
Of interest, the genetic backgrounds of the cell lines
that responded the best to the combination therapy with
AEE788 and patupilone were different with regard to the
three main glioma pathways: TP53, PTEN, and p14/p16
(Fig. 1A). Whereas SF767 cells are wild-type at all three loci,
LN71 cells are either mutated or null (39), suggesting that
such a combination could be applied to a wide spectrum of
gliomas. When analyzing the activation status of EGFR,
PKB/AKT, and ERK as readouts for critical pathways in
the glioblastoma signaling network, we found that syner-
gistic induction of apoptosis by combining patupilone and
AEE788 was paralleled by inactivation of PKB/AKT and
ERK. Conversely, the two critical cell signaling mediators
remained active in glioblastoma cells that did not show this
drug synergism. Although AEE788, patupilone, and U0126,
applied individually, reduced glioblastoma cell growth,
AEE788/patupilone and U0126/wortmannin combinations
Figure 5. Phorbol ester TPA antagonizes induction of
apoptosis and maintains AKT and ERK1/2 activities. A,
cells were treated with 20 and 100 nmol/L of TPA in the
presence or absence of wortmannin (W) and U0126 (U)
for 3 d, whereby the additions were renewed every day.
Cell extracts were prepared by the addition of SDS
sample buffer, and Western blot analysis was done.
U0126, 20 Amol/L; wortmannin, 1 Amol/L; TPA, 20 or
100 nmol/L. B, cells were treated in the same way for
4 d and the percentage of dead cells was determined by
flow cytometry.
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did not affect cell growth in a synergistic manner,
suggesting that these processes are driven by distinct
pathways. The importance of the two signaling pathways
PI3K/PKB and RAS/RAF/MEK/ERK for glioblastoma
signaling is further supported by the finding that PI3K is
activated in the majority of human glioblastoma either by
loss of PTEN function (38, 39) or by activating mutations of
PI3KCA (22), whereas growth factor stimulation causes
activation of RAS in glioblastoma (52). Further evidence
stems from a murine transgenic glioblastoma model, in
which simultaneous activation of RAS and PKB gives rise
to malignant gliomas (53, 54). Glioma animal models have
further shown that the combination of ectopic expression of
activated RAS and AKT in the glial lineage (23) led to
spontaneous induction of murine gliomas, whereas an
activated allele of either RAS or AKT alone failed to induce
tumor formation. In analogy to this animal model and the
effects on signaling induced by the described synergism,
we hypothesized that direct inhibition of signaling medi-
ators downstream of EGFR within the PI3K/PKB and
RAS/RAF/MEK/ERK pathways will overcome glioblasto-
ma cell resistance. Therefore, we specifically blocked
activity of both MEK and PI3K, which induced strong
apoptosis in a subgroup of glioblastoma cell lines,
indicating a critical role of these two pathways in
glioblastoma signaling. Combining the MEK inhibitor
U0126 and the PI3K inhibitor wortmannin led to synergistic
induction of apoptosis in LN215 and LN229 cell lines.
Interestingly, although phosphorylation of ERK1/2 and
PKB/AKT was decreased in all cell lines, it was not
associated with apoptosis in resistant lines, suggesting
additional defects in the proapoptotic machinery. Activa-
tion of protein kinase C and ERK1/2 by TPA counteracted
U0126- and wortmannin-dependent apoptosis, confirming
the specificity of drug effect.
An unresolved question is at which cellular level the
intervention has to take place. Our data argue that
combined blocking of signaling mediators downstream of
growth factor receptors, interfering with the signaling
cross-talk, may be more effective than inhibition of a single
cell surface receptor (e.g., EGFR; ref. 13). This view is
supported by other findings in glioblastoma cell lines,
where inhibition of PKB/AKT could be counteracted by a
stimulation of insulin-like growth factor receptor-I, result-
ing in sustained activation of PI3K (19, 20).
In conclusion, our results indicate that the induction of
apoptosis in glioblastoma cell lines requires drug combi-
nation, which down-regulate distinct pathways. Blocking
EGFR activation alone did not induce apoptosis unless
complemented with the microtubule stabilizer patupilone.
If PKIs were targeted without the help of cytotoxic drugs,
combined inhibition of MEK and PI3K was found to be
the most efficient combination to induce glioblastoma cell
death. Drug effects were independent of mutation statuses
at the major glioblastoma pathways (Fig. 1A). Additional
studies are needed to develop other target for treatment of
resistant glioblastoma cells to directly down-regulate key
members of the critical pathways.
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